NATIONAL QUALITY FORUM

Measure Evaluation 4.1 January 2010

This form contains the measure information submitted by stewards. Blank fields indicate no information was provided. Attachments also may have been submitted and are provided to reviewers. The sub-criteria and most of the footnotes from the evaluation criteria are provided in Word comments and will appear if your cursor is over the highlighted area (or in the margin if your Word program is set to show revisions in balloons). Hyperlinks to the evaluation criteria and ratings are provided in each section.

TAP/Workgroup (if utilized): Complete all yellow highlighted areas of the form. Evaluate the extent to which each sub-criterion is met. Based on your evaluation, summarize the strengths and weaknesses in each section.

Note: If there is no TAP or workgroup, the SC also evaluates the sub-criteria (yellow highlighted areas).

Steering Committee: Complete all pink highlighted areas of the form. Review the workgroup/TAP assessment of the sub-criterion, noting any areas of disagreement; then evaluate the extent to which each major criterion is met; and finally, indicate your recommendation for the endorsement. Provide the rationale for your ratings.

Evaluation ratings of the extent to which the criteria are met

C = Completely (unquestionably demonstrated to meet the criterion)

P = Partially (demonstrated to partially meet the criterion)

M = Minimally (addressed BUT demonstrated to only minimally meet the criterion)

N = Not at all (NOT addressed; OR incorrectly addressed; OR demonstrated to NOT meet the criterion)

NA = Not applicable (only an option for a few sub-criteria as indicated)

(for NQF staff use) NQF Review #: ACP-042-10 NQF Project: Ambulatory Care - Additional Outpatient Measures 2010

MEASURE DESCRIPTIVE INFORMATION

De.1 Measure Title: Patient(s) with frequent ER migraine encounters or frequent acute migraine medication use that had an office visit in last 6 reported months.

De.2 Brief description of measure: This measure identifies patients with frequent migraine ER encounters or frequent migraine abortive medication use that had an office visit within the last 6 reported months.

1.1-2 Type of Measure: process

De.3 If included in a composite or paired with another measure, please identify composite or paired measure Does not apply

De.4 National Priority Partners Priority Area: care coordination

De.5 IOM Quality Domain: patient-centered

De.6 Consumer Care Need: Living With Illness

CONDITIONS FOR CONSIDERATION BY NQF

Four conditions must be met before proposed measures may be considered and evaluated for suitability as voluntary consensus standards:	NQF Staff
A . The measure is in the public domain or an intellectual property (measure steward agreement) is signed. <i>Public domain only applies to governmental organizations. All non-government organizations must sign a measure steward agreement even if measures are made publicly and freely available.</i>	
A.1 Do you attest that the measure steward holds intellectual property rights to the measure and the right to use aspects of the measure owned by another entity (e.g., risk model, code set)? Yes	
A.2 Indicate if Proprietary Measure (as defined in measure steward agreement): proprietary measure	Α
A.3 Measure Steward Agreement: agreement signed and submitted	Υ
A.4 Measure Steward Agreement attached: Measure steward addendum_Ingenix 012510-	N

634000246914537214.doc	
B. The measure owner/steward verifies there is an identified responsible entity and process to maintain and update the measure on a schedule that is commensurate with the rate of clinical innovation, but at least every 3 years. Yes, information provided in contact section	B Y□ N□
 C. The intended use of the measure includes <u>both</u> public reporting <u>and</u> quality improvement. Purpose: public reporting, quality improvement Payment Incentive, Accountability 	C Y□ N□
 D. The requested measure submission information is complete. Generally, measures should be fully developed and tested so that all the evaluation criteria have been addressed and information needed to evaluate the measure is provided. Measures that have not been tested are only potentially eligible for a time-limited endorsement and in that case, measure owners must verify that testing will be completed within 12 months of endorsement. D.1Testing: Yes, fully developed and tested D.2 Have NQF-endorsed measures been reviewed to identify if there are similar or related measures? 	D
Yes	N
(for NQF staff use) Have all conditions for consideration been met? Staff Notes to Steward (<i>if submission returned</i>):	Met Y N
Staff Notes to Reviewers (issues or questions regarding any criteria):	
Staff Reviewer Name(s):	

TAP/Workgroup Reviewer Name: Steering Committee Reviewer Name:

1. IMPORTANCE TO MEASURE AND REPORT

Extent to which the specific measure focus is important to making significant gains in health care quality (safety, timeliness, effectiveness, efficiency, equity, patient-centeredness) and improving health outcomes for a specific high impact aspect of healthcare where there is variation in or overall poor performance. Measures must be judged to be important to measure and report in order to be evaluated against the Eval *remaining criteria*. (evaluation criteria) 1a. High Impact Rating (for NQF staff use) Specific NPP goal: 1a.1 Demonstrated High Impact Aspect of Healthcare: patient/societal consequences of poor quality, affects large numbers 1a.2 1a.3 Summary of Evidence of High Impact: Migraine is a very common disorder. An estimated 18% of women and 6% of men experience migraine, but many go undiagnosed and undertreated (1). 1a C P 1a.4 Citations for Evidence of High Impact: 1. American Academy of Neurology. Practice parameter: M N evidence-based guidelines for migraine headaches (an evidence-based review). Report on the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-63. 1b. Opportunity for Improvement

1b.1 Benefits (improvements in quality) envisioned by use of this measure: This measure will identify patients with evidence of poor disease control who would benefit from a face-to-face provider encounter. This evaluation is an opportunity to review of behavioral and medication interventions that could improve disease control, improve quality of life, and reduce ER/hospital admissions or other adverse events.

1b C___ P___ M___ N___

2

Comment [KP1]: 1a. The measure focus addresses:

•a specific national health goal/priority identified by NQF's National Priorities Partners; OR

 a demonstrated high impact aspect of healthcare (e.g., affects large numbers, leading cause of morbidity/mortality, high resource use (current and/or future), severity of illness, and patient/societal consequences of poor quality).

Comment [KP2]: 1b. Demonstration of quality problems and opportunity for improvement, i.e., data demonstrating considerable variation, or overall poor performance, in the quality of care across providers and/or population groups (disparities in care).

1b.2 Summary of data demonstrating performance gap (variation or overall poor performance) across providers: Using a geographically diverse 15 million member benchmark database (this database represents predominately a commercial population less than 65 year of age) the compliance rate was 66.0 percent, indicating a clear gap in care and opportunity for care improvement. 1b.3 Citations for data on performance gap: Ingenix EBM Connect benchmark results, September 2009 1b.4 Summary of Data on disparities by population group: None 1b.5 Citations for data on Disparities: 1c. Outcome or Evidence to Support Measure Focus 1c.1 Relationship to Outcomes (For non-outcome measures, briefly describe the relationship to desired outcome. For outcomes, describe why it is relevant to the target population): This measure will identify patients with evidence of poor disease control who would benefit from a face-to-face provider encounter. This evaluation will result in a review of behavioral and medication interventions that could improve disease control, improve quality of life, and reduce ER/hospital admissions or other adverse events. 1c.2-3. Type of Evidence: evidence based guideline, expert opinion 1c.4 Summary of Evidence (as described in the criteria; for outcomes, summarize any evidence that healthcare services/care processes influence the outcome): According to an AAN migraine guideline, it is appropriate to link the intensity of care with the level of disability and symptoms; it is not appropriate to continue ineffective or poorly tolerated medication(1). Identification of patients with poor disease control provide an opportunity to review migraine triggers, acute management options, and prophylactic/preventive treatment regimens (1,2). Appropriate pharmacological or analgesic treatment of acute headache should generally not exceed more than two days per week on a regular basis (2). **1c.5** Rating of strength/quality of evidence (also provide narrative description of the rating and by whom): This is an expert panel consensus recommendation from the American Academy of Neurology and the Institute for Clinical Systems Improvement (ICSI). 1c.6 Method for rating evidence: This is an expert consensus recommendation from the Quality Standards Subcommittee (QSS) of the American Academy of Neurology (AAN) in collaboration with The US Headache Consortium which includes the following organizations: the American Academy of Family Physicians, AAN, American Headache Society (formerly the American Association for the Study of Headache), American College of Emergency Physicians, American College of Physicians-American Society of Internal Medicine, American Osteopathic Association, and National Headache Foundation. In addition, our definition of frequent medication use for acute headache treatment is based on an ICSI expert panel consensus recommendation. 1c.7 Summary of Controversy/Contradictory Evidence: The frequency of health care visits and assessments depends upon the patient's initial clinical severity and migraine control. There are no clinical trials that define ideal follow up care when someone has poor migraine control. Therefore, this measure is based on expert panel consensus, including two published migraine guidelines. This specific measure identifies a small, select subset of patients with evidence of poorly controlled 1c C P migraines. A patient was defined as having poor migraine control if there was evidence of two or more emergency room (ER) encounters for migraine/headache care or frequent use of acute migraine medications. Of more than 78,000 patients that we identified as having migraines, only 4 percent met the M denominator definition for this measure (i.e., poor migraine control). N Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable

Comment [k3]: 1 Examples of data on opportunity for improvement include, but are not limited to: prior studies, epidemiologic data, measure data from pilot testing or implementation. If data are not available, the measure focus is systematically assessed (e.g., expert panel rating) and judged to be a quality problem.

Comment [k4]: 1c. The measure focus is: •an outcome (e.g., morbidity, mortality, function, health-related quality of life) that is relevant to, or associated with, a national health goal/priority, the condition, population, and/or care being addressed; OR

•if an intermediate outcome, process, structure, etc., there is evidence that supports the specific measure focus as follows: oIntermediate outcome - evidence that the measured intermediate outcome (e.g., blood pressure, Hba1c) leads to improved health/avoidance of harm or cost/benefit. oProcess - evidence that the measured clinical or administrative process leads to improved health/avoidance of harm and if the measure focus is on one step in a multistep care process, it measures the step that has the greatest effect on improving the specified desired outcome(s). oStructure - evidence that the measured

structure supports the consistent delivery of effective processes or access that lead to improved health/avoidance of harm or cost/benefit.

oPatient experience - evidence that an association exists between the measure of patient experience of health care and th [1]

Comment [k5]: 4 Clinical care processes typically include multiple steps: assess \rightarrow identify problem/potential problem \rightarrow choose/plan intervention (with patient input) \rightarrow provide intervention \rightarrow evaluate impact on health status. If the measure focus is one step in such a multi-step process, the step with the greatest effect on the desired outcome should be selected as the focus of measurement. For example, although assessment of immunization status and recommending immunization are necessary steps, they are not sufficient to achieve the desired impact on health status patients must be vaccinated to achieve immunity. This does not preclude consideration of measures of preventive

screening interventions where there is a ... [2]

Comment [k6]: 3 The strength of the body of evidence for the specific measure focus should be systematically assessed and rated (e.g., USPSTF grading system

http://www.ahrq.gov/clinic/uspstf07/method s/benefit.htm). If the USPSTF grading system was not used, the grading system is explained including how it relates to the USPSTF grades or why it does not. However, evidence is not limited to quantitative studies and the best type of evidence depends upon the question being studied (e.g., randomized controlled trials appropriate for studying drug efficacy are not well suited for complex system changes). When qualitative studies are used, appropriate qualitative research criteria are used to judge the strength of the evidence.

1c.8 Citations for Evidence (other than guidelines): see 1c.10 1c.9 Quote the Specific guideline recommendation (including guideline number and/or page number): AAN, pages 2-3 (1): Treatment of migraine. Migraine varies in frequency, duration, and disability among sufferers and between attacks. It is appropriate to link the intensity of care with the level of disability and symptoms such as nausea and vomiting (stratified care) for the acute treatment of symptoms of an ongoing attack. It is not appropriate to continue ineffective or poorly tolerated medication in a sequential and arbitrary manner (step care). Consider preventive treatment (given on an ongoing basis whether or not an attack is present) for those patients whose migraine has a substantial impact on their lives and have not responded to acute care, or where the frequency of migraine attacks is such that the reliance on acute care medications would increase the potential for drug-induced (rebound) headache. The goals of longterm migraine treatment, both pharmacologic and nonpharmacologic, are to: •?Reduce attack frequency, severity, and disability •?Reduce reliance on poorly tolerated, ineffective, or unwanted acute pharmacotherapies •?Improve quality of life •?Avoid acute headache medication escalation •?Educate and enable patients to manage their disease to enhance personal control of their migraine Reduce headache-related distress and psychological symptoms Guard against medication-overuse headache ("rebound headache" or "drug-induced headache"). Frequent use of acute medications (ergotamine [not DHE], opiates, triptans, simple analgesics, and mixed analgesics containing butalbital, caffeine, or isometheptene) is generally thought to cause medication-overuse headache. Many experts limit acute therapy to two headache days per week on a regular basis. Patients with medication overuse should use preventive therapy. ICSI, page 12 (2): Appropriate pharmacological or analgesic treatment of acute headache should generally not exceed more than two days per week on a regular basis. More treatment other than this may result in medication-overuse chronic daily headaches. Criteria for Prophylactic Treatment: - Three or more severe migraine attacks per month that fail to respond adequately to symptomatic therapy. Less frequent but protracted attacks that impair the patient's quality of life. - Patient is interested in prophylactic treatment. 1c.10 Clinical Practice Guideline Citation: 1. American Academy of Neurology. Practice parameter: evidence-based guidelines for migraine headaches (an evidence-based review). Report on the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-63. 2. Institute for Clinical Systems Improvement (ICSI). Health Care Guideline: Diagnosis and Treatment of Headache (Released March 2009). Accessed February 2, 2010. URL: http://www.icsi.org 1c.11 National Guideline Clearinghouse or other URL: http://www.neurology.org/cgi/content/full/55/6/754 and http:www.icsi.org 1c.12 Rating of strength of recommendation (also provide narrative description of the rating and by whom): This is an expert panel consensus recommendation from the American Academy of Neurology and ICSI. 1c.13 Method for rating strength of recommendation (If different from USPSTF system, also describe rating and how it relates to USPSTF): This is an expert consensus recommendation from the Quality Standards Subcommittee (QSS) of the American Academy of Neurology (AAN) in collaboration with The US Headache Consortium which includes the following organizations: the American Academy of Family Physicians, AAN, American Headache Society (formerly the American Association for the Study of Headache), American College of Emergency Physicians,

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable

Comment [k7]: USPSTF grading system http://www.ahrq.gov/clinic/uspstf/grades.ht
 m: A - The USPSTF recommends the service.
 There is high certainty that the net benefit is substantial. B - The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial. C - The USPSTF recommends against routinely providing the service. There may be considerations that support providing the service in an individual patient. There is at least moderate certainty that the net benefit is small. Offer or provide this service only if other considerations support the offering or providing the service in an individual patient. D - The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits. I - The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.

NQF #AC	P-042-10	
merican College of Physicians—American Society of Internal Medicine, American Osteopathic Association, nd National Headache Foundation. This would be equivalent to the USPSTF grade B/C classification.		
n addition, our definition of frequent acute medication use is based on an ICSI expert panel consensus ecommendation.		
c.14 Rationale for using this guideline over others: This AAN guideline, producted in collaboration with several other specialty organizations, is the main nationally recognized guideline that addresses evaluation and management of migraines.		
CSI is an independent, non-profit organization that helps its members provide evidence-based health care ervices to people in Minnesota and surrounding states. ICSI is comprised of 53 medical groups representing ,000 physicians. Its demonstrated collaborative and innovative processes enable ICSI to unite diverse takeholders in the health care system to deliver patient-centered and value-driven care. This ICSI uideline is used to define a threshold for frequent acute migraine prophylaxis use.		
AP/Workgroup: What are the strengths and weaknesses in relation to the sub-criteria for Importance of Measure and Report?	1	
teering Committee: Was the threshold criterion, <i>Importance to Measure and Report</i> , met? Rationale:	1 Y N	
2. SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES		
xtent to which the measure, <u>as specified</u> , produces consistent (reliable) and credible (valid) results about he quality of care when implemented. (evaluation criteria)	Eval Rating	
2a. MEASURE SPECIFICATIONS		
3.1 Do you have a web page where current detailed measure specifications can be obtained? 3.2 If yes, provide web page URL:		
a. Precisely Specified		
ta.1 Numerator Statement (<i>Brief, text description of the numerator - what is being measured about the arget population, e.g. target condition, event, or outcome</i>) : vatients who are diagnosed with migraine and who have had frequent ER encounters or frequent acute nedication use, who had an office visit during the following time period: last 180 days prior to the end of the report period through 90 days after the end of the report period		
a.2 Numerator Time Window (The time period in which cases are eligible for inclusion in the numerator):		
ast 180 days prior to the end of the report period through 90 days after the end of the report period		
A.3 Numerator Details (<i>All information required to collect/calculate the numerator, including all codes, ogic, and definitions</i>): Vatients who have had an ambulatory visit (code sets PR0111, RV0111) with a diagnosis of migraine (code et DX0101) during the following time period: last 180 days prior to the end of the report period through 90 lays after the end of the report period		
Cd. Set Cd St Descrp. DX Code DX Code Description XX0101 Migraine 346 MIGRAINE XX0101 Migraine 346.0 MIGRAINE WITH AURA XX0101 Migraine 346.00 MIGRAINE W/AURA W/O INTRACT W/O STATUS MIGRNOSUS XX0101 Migraine 346.01 MIGRAINE W/AURA W/O INTRACT W/O STATUS MIGRNOSUS XX0101 Migraine 346.02 MIGRAINE W/AURA W/O INTRACT W/O STATUS MIGRAINOSUS XX0101 Migraine 346.02 MIGRAINE W/AURA W/O INTRACT W/STATUS MIGRAINOSUS XX0101 Migraine 346.03 MIGRAINE W/AURA W/INTRACTBL W/STATUS MIGRAINOSUS	2a- specs C□ P□	

Comment [KP8]: 2a. The measure is well defined and precisely specified so that it can be implemented consistently within and across organizations and allow for comparability. The required data elements are of high quality as defined by NQF's Health Information Technology Expert Panel (HITEP).

NQF #ACP-042-10

				NQF #ACP-	-042-1
DX0101	Migraine	346.11	MIGRAINE W/O AURA W/INTRACT W/O STATUS MIGRNOSUS		
DX0101	Migraine	346.12	MIGRAINE W/O AURA W/O INTRACT W/STATUS MIGRNOSUS		
	Migraine	346.13	MIGRAINE W/O AURA W/INTRACT W/STATUS MIGRAINOSUS		
DX0101	Migraine	346.2	VARIANTS OF MIGRAINE NOT ELSEWHERE CLASSIFIED		
DX0101	Migraine	346.20	VAR MIGRAINE NEC W/O INTRACT W/O STAT MIGRNOSUS		
DX0101	Migraine	346.21	VAR MIGRAINE NEC W/INTRACT W/O STATUS MIGRNOSUS		
DX0101	Migraine	346.22	VAR MIGRAINE NEC W/O INTRACT W/STATUS MIGRNOSUS		
DX0101	Migraine	346.23	VAR MIGRAINE NEC W/INTRACT W/STATUS MIGRAINOSUS		
DX0101	Migraine	346.3	HEMIPLEGIC MIGRAINE		
DX0101	Migraine	346.30	HEMI MIGRAINE W/O INTRACT W/O STATUS MIGRAINOSUS		
DX0101	Migraine	346.31	HEMI MIGRAINE W/INTRACTBL W/O STATUS MIGRAINOSUS		
DX0101	Migraine	346.32	HEMI MIGRAINE W/O INTRACTBL W/STATUS MIGRAINOSUS		
DX0101	Migraine	346.33	HEMI MIGRAINE W/INTRACTABLE W/STATUS MIGRAINOSUS		
DX0101	Migraine	346.5	PERSISTENT MIGRAINE AURA W/O CEREBRAL INFARCTION		
DX0101	Migraine	346.50	PERSIST MIGRAINE AURA W/O CI W/O INTRACT W/O SM		
DX0101	Migraine	346.51	PERSISTENT MIGRAINE AURA W/O CI W/INTRACT W/O SM		
DX0101	Migraine	346.52	PERSISTENT MIGRAINE AURA W/O CI W/O INTRACT W/SM		
DX0101	Migraine	346.53	PERSISTENT MIGRAINE AURA W/O CI W/INTRACTBL W/SM		
DX0101	Migraine	346.6	PERSISTENT MIGRAINE AURA WITH CEREBRAL INFARCT		
DX0101	Migraine	346.60	PERSISTENT MIGRAINE AURA W/CI W/O INTRACT W/O SM		
	Migraine	346.61	PERSISTENT MIGRAINE AURA W/CI W/INTRACTBL W/O SM		
DX0101	Migraine	346.62	PERSISTENT MIGRAINE AURA W/CI W/O INTRACTBL W/SM		
DX0101	Migraine	346.63	PERSISTENT MIGRAINE AURA W/CI W/INTRACTABLE W/SM		
DX0101	Migraine		CHRONIC MIGRAINE WITHOUT AURA		
	Migraine	346.70	CHRONIC MIGRAINE W/O AURA W/O INTRACTABLE W/O SM		
	Migraine		CHRONIC MIGRAINE W/O AURA W/INTRACTABLE W/O SM		
	Migraine		CHRONIC MIGRAINE W/O AURA W/O INTRACTABLE W/SM		
	Migraine		CHRONIC MIGRAINE W/O AURA W/INTRACTABLE W/SM		
	Migraine		OTHER FORMS OF MIGRAINE		
	Migraine		OTH MIGRAINE W/O INTRACT W/O STATUS MIGRAINOSUS		
	Migraine		OTH MIGRAINE W/INTRACTABL W/O STATUS MIGRAINOSUS		
	Migraine		OTH MIGRAINE W/O INTRACTABL W/STATUS MIGRAINOSUS		
	Migraine		OTH MIGRAINE W/INTRACTABLE W/STATUS MIGRAINOSUS		
DX0101	Migraine		MIGRAINE UNSPECIFIED		
	Migraine		MIGRAINE UNSP W/O INTRACT W/O STATUS MIGRAINOSUS		
	Migraine		MIGRAINE UNSP W/INTRACTBL W/O STATUS MIGRAINOSUS		
	Migraine		MIGRAINE UNSP W/O INTRACTBL W/STATUS MIGRAINOSUS		
DX0101	Migraine	346.93	MIGRAINE UNSP W/INTRACTABLE W/STATUS MIGRAINOSUS		
Code Se	et Code Set	Descript	ion Procedure Code		
PR0111	Ambulator	ry visit c	odes99201		
PR0111	Ambulator	ry visit c	odes99202		
PR0111	Ambulator	ry visit c	odes99203		
PR0111	Ambulator	ry visit c	odes99204		
PR0111	Ambulator	ry visit c	odes99205		
PR0111	Ambulator	ry visit c	odes99211		
	Ambulator				
PR0111					
	Ambulator				
PR0111					
PR0111	Ambulator	ry visit c	Odesyy2/3		
				-	

		NQF #ACP-042-10
PR0111	Ambulatory visit codes99274	
PR0111	Ambulatory visit codes99275	
PR0111	Ambulatory visit codes99341	
PR0111	Ambulatory visit codes99342	
PR0111	Ambulatory visit codes99343	
	Ambulatory visit codes99344	
	Ambulatory visit codes99345	
	Ambulatory visit codes99347	
	Ambulatory visit codes99348	
	Ambulatory visit codes99349	
PR0111	Ambulatory visit codes99350	
	Ambulatory visit codes99381	
	Ambulatory visit codes99382	
	Ambulatory visit codes99383	
	Ambulatory visit codes99384	
	Ambulatory visit codes99385	
	Ambulatory visit codes99386	
	Ambulatory visit codes99387	
	Ambulatory visit codes99391	
	Ambulatory visit codes99392	
	Ambulatory visit codes99393 Ambulatory visit codes99394	
	Ambulatory visit codes 99395	
	Ambulatory visit codes99396	
	Ambulatory visit codes97397	
PR0111	Ambulatory visit codes97401	
	Ambulatory visit codes99402	
	Ambulatory visit codes99403	
	Ambulatory visit codes99404	
	Ambulatory visit codes99411	
	Ambulatory visit codes99412	
	Ambulatory visit codes99420	
	Ambulatory visit codes99429	
Code Set	Code Set Description Revenue Code	
	Ambulatory visit codes 0983	
2a.4 Den	ominator Statement (Brief, text description of the denominator - target population beir	1g
measure		Ŭ
	6 years of age or older who are diagnosed with migraine and who have had frequent ER er ent acute medication use	ncounters
20 E T	act non-ulation gondor. Formalo, Malo	
	get population gender: Female, Male get population age range: Patients 6 years of age or older at the end of the report period	t
2a.7 Den denomin	ominator Time Window (The time period in which cases are eligible for inclusion in the ator):	
	nonths prior to the end of the report period for confirmation that the patient had migraine	e; 180
days prio	or to the end of the report period to determine whether the patient had frequent ER encou prior to the end of the report period frequent acute medication use	unters;
populati	nominator Details (All information required to collect/calculate the denominator - the ta on being measured - including all codes, logic, and definitions): for inclusion in the denominator are as follows:	rget
 All matched and a constraint of the second of the second se	ales or females that are 6 years of age or older at the end of the report period nt must have been continuously enrolled in medical benefits throughout the 12 months pri ne report period AND pharmacy benefit plan for 6 months prior to the end of the report pe	riod.
rne stan	dard EBM Connect [®] enrollment break logic allows unlimited breaks in coverage of no more	e unan 45



	NQF #AC
Calculate the tota	I number of procedures in medical claims. Note: Exclude the last claim within this time
period.	
vi. The sum o	of the Equivalent Doses (EqDose) for butalbital containing medication (code set RX-28)
was greater than a	a threshold of 100 tablets/ capsules during the following time period: last 120 days of the
report period. No	te: Exclude the last claim within this time period.
vii. The sum	of the Equivalent Doses (EqDose) for midrin-type medication (code set RX-76) was
greater than a thr	eshold of 150 capsules during the following time period: last 120 days of the report
	lude the last claim within this time period.
Cd. Set Cd St Desc	crp. DX Code DX Code Description
DX0101 Migraine	346 MIGRAINE
DX0101 Migraine	346.0 MIGRAINE WITH AURA
DX0101 Migraine	346.00 MIGRAINE W/AURA W/O INTRACT W/O STATUS MIGRNOSUS
DX0101 Migraine	346.01 MIGRAINE W/AURA W/INTRACT W/O STATUS MIGRAINOSUS
DX0101 Migraine	346.02 MIGRAINE W/AURA W/O INTRACT W/STATUS MIGRAINOSUS
DX0101 Migraine	346.03 MIGRAINE W/AURA W/INTRACTBL W/STATUS MIGRAINOSUS
DX0101 Migraine	346.1 MIGRAINE WITHOUT AURA
DX0101 Migraine	346.10 MIGRAINE W/O AURA W/O INTRACT W/O STAT MIGRNOSUS
DX0101 Migraine	346.11 MIGRAINE W/O AURA W/INTRACT W/O STATUS MIGRNOSUS
DX0101 Migraine	346.12 MIGRAINE W/O AURA W/O INTRACT W/STATUS MIGRNOSUS
DX0101 Migraine	346.13 MIGRAINE W/O AURA W/INTRACT W/STATUS MIGRAINOSUS
DX0101 Migraine	346.2 VARIANTS OF MIGRAINE NOT ELSEWHERE CLASSIFIED
DX0101 Migraine	346.20 VAR MIGRAINE NEC W/O INTRACT W/O STAT MIGRNOSUS
DX0101 Migraine	346.21 VAR MIGRAINE NEC W/INTRACT W/O STATUS MIGRNOSUS
DX0101 Migraine	346.22 VAR MIGRAINE NEC W/O INTRACT W/STATUS MIGRNOSUS
DX0101 Migraine	346.23 VAR MIGRAINE NEC W/INTRACT W/STATUS MIGRAINOSUS
DX0101 Migraine	346.3 HEMIPLEGIC MIGRAINE
DX0101 Migraine	346.30 HEMI MIGRAINE W/O INTRACT W/O STATUS MIGRAINOSUS
DX0101 Migraine	346.31 HEMI MIGRAINE W/INTRACTBL W/O STATUS MIGRAINOSUS
DX0101 Migraine	346.32 HEMI MIGRAINE W/O INTRACTBL W/STATUS MIGRAINOSUS
DX0101 Migraine	346.33 HEMI MIGRAINE W/INTRACTABLE W/STATUS MIGRAINOSUS
DX0101 Migraine	346.5 PERSISTENT MIGRAINE AURA W/O CEREBRAL INFARCTION
DX0101 Migraine	346.50 PERSIST MIGRAINE AURA W/O CI W/O INTRACT W/O SM
DX0101 Migraine	346.51 PERSISTENT MIGRAINE AURA W/O CI W/INTRACT W/O SM
DX0101 Migraine	346.52 PERSISTENT MIGRAINE AURA W/O CI W/O INTRACT W/SM
DX0101 Migraine	346.53 PERSISTENT MIGRAINE AURA W/O CI W/INTRACTBL W/SM
DX0101 Migraine	346.6 PERSISTENT MIGRAINE AURA WITH CEREBRAL INFARCT
DX0101 Migraine	346.60 PERSISTENT MIGRAINE AURA W/CI W/O INTRACT W/O SM
DX0101 Migraine	346.61 PERSISTENT MIGRAINE AURA W/CI W/INTRACTBL W/O SM
DX0101 Migraine	346.62 PERSISTENT MIGRAINE AURA W/CI W/O INTRACTALI E W/SM
DX0101 Migraine	346.63 PERSISTENT MIGRAINE AURA W/CI W/INTRACTABLE W/SM
DX0101 Migraine	346.7 CHRONIC MIGRAINE WITHOUT AURA
DX0101 Migraine	346.70 CHRONIC MIGRAINE W/O AURA W/O INTRACTABLE W/O SM 346.71 CHRONIC MIGRAINE W/O AURA W/INTRACTABLE W/O SM
DX0101 Migraine	
DX0101 Migraine	346.72 CHRONIC MIGRAINE W/O AURA W/O INTRACTABLE W/SM
DX0101 Migraine DX0101 Migraine	346.73 CHRONIC MIGRAINE W/O AURA W/INTRACTABLE W/SM 346.8 OTHER FORMS OF MIGRAINE
•	346.80 OTH MIGRAINE W/O INTRACT W/O STATUS MIGRAINOSUS
DX0101 Migraine DX0101 Migraine	346.81 OTH MIGRAINE W/O INTRACTABL W/O STATUS MIGRAINOSUS
DX0101 Migraine	346.82 OTH MIGRAINE W/O INTRACTABL W/O STATUS MIGRAINOSUS
DX0101 Migraine	346.83 OTH MIGRAINE W/O INTRACTABLE W/STATUS MIGRAINOSUS 346.83 OTH MIGRAINE W/INTRACTABLE W/STATUS MIGRAINOSUS
DX0101 Migraine	346.9 MIGRAINE UNSPECIFIED
DX0101 Migraine	346.90 MIGRAINE UNSPECIFIED 346.90 MIGRAINE UNSP W/O INTRACT W/O STATUS MIGRAINOSUS
DX0101 Migraine	346.91 MIGRAINE UNSP W/O INTRACTBL W/O STATUS MIGRAINOSOS
DX0101 Migraine	346.92 MIGRAINE UNSP W/O INTRACTBE W/O STATUS MIGRAINOSUS
DX0101 Migraine	346.92 MIGRAINE UNSP W/O INTRACTABLE W/STATUS MIGRAINOSUS 346.93 MIGRAINE UNSP W/INTRACTABLE W/STATUS MIGRAINOSUS
everet wilding	
Code Set Code Se	et Description Procedure Code

 $Rating: \ C=Completely; \ P=Partially; \ M=Minimally; \ N=Not \ at \ all; \ NA=Not \ applicable$

			NQF #ACP	-042-10
PR0107	Professional encounter	99201		
PR0107	Professional encounter	99202		
PR0107	Professional encounter	99203		
PR0107	Professional encounter	99204		
PR0107	Professional encounter	99205		
PR0107	Professional encounter	99211		
PR0107	Professional encounter	99212		
PR0107	Professional encounter	99213		
PR0107	Professional encounter	99214		
PR0107	Professional encounter	99215		
PR0107	Professional encounter	99217		
PR0107	Professional encounter	99218		
PR0107	Professional encounter	99219		
PR0107	Professional encounter	99220		
PR0107	Professional encounter	99221		
PR0107	Professional encounter	99222		
PR0107	Professional encounter	99223		
PR0107	Professional encounter	99231		
PR0107	Professional encounter	99232		
PR0107	Professional encounter	99233		
PR0107	Professional encounter Professional encounter	99234		
PR0107		99235		
PR0107 PR0107	Professional encounter Professional encounter	99236 99238		
PR0107 PR0107	Professional encounter	99230		
PR0107	Professional encounter	99241		
PR0107	Professional encounter	99242		
PR0107	Professional encounter	99243		
PR0107	Professional encounter	99244		
PR0107	Professional encounter	99245		
PR0107	Professional encounter	99251		
PR0107	Professional encounter	99252		
PR0107	Professional encounter	99253		
PR0107	Professional encounter	99254		
PR0107	Professional encounter	99255		
PR0107	Professional encounter	99261		
PR0107	Professional encounter	99262		
PR0107	Professional encounter	99263		
PR0107	Professional encounter	99271		
PR0107	Professional encounter	99272		
PR0107	Professional encounter	99273		
PR0107	Professional encounter	99274		
PR0107	Professional encounter	99275		
PR0107	Professional encounter	99281		
PR0107	Professional encounter	99282		
PR0107	Professional encounter	99283		
PR0107	Professional encounter	99284		
PR0107	Professional encounter	99285		
PR0107	Professional encounter	99301		
PR0107 PR0107	Professional encounter Professional encounter	99302 99303		
PR0107 PR0107	Professional encounter	99303 99304		
PR0107 PR0107	Professional encounter	99304 99305		
PR0107 PR0107	Professional encounter	99305 99306		
PR0107	Professional encounter	99300		
PR0107 PR0107	Professional encounter	99307 99308		
PR0107	Professional encounter	99308		
PR0107	Professional encounter	99310		
	risissional cheoditter	//510		

		NQF #/	ACP-042-10
PR0107	Professional encounter	99311	
PR0107	Professional encounter	99312	
PR0107	Professional encounter	99313	
PR0107	Professional encounter	99315	
PR0107	Professional encounter	99316	
PR0107	Professional encounter	99318	
PR0107	Professional encounter	99341	
PR0107	Professional encounter	99342	
PR0107	Professional encounter	99343	
PR0107	Professional encounter	99344	
PR0107	Professional encounter	99345	
PR0107	Professional encounter	99347	
PR0107	Professional encounter	99348	
PR0107	Professional encounter	99349	
PR0107	Professional encounter	99350	
PR0107	Professional encounter	99381	
PR0107	Professional encounter	99382	
PR0107	Professional encounter	99383	
PR0107	Professional encounter	99384	
PR0107	Professional encounter	99385	
PR0107	Professional encounter	99386	
PR0107	Professional encounter	99387	
PR0107 PR0107	Professional encounter Professional encounter	99391 99392	
PR0107 PR0107	Professional encounter	99393	
PR0107 PR0107	Professional encounter	99394	
PR0107 PR0107	Professional encounter	99395	
PR0107 PR0107	Professional encounter	99396	
PR0107	Professional encounter	99397	
PR0107	Professional encounter	99401	
PR0107	Professional encounter	99402	
PR0107	Professional encounter	99403	
PR0107	Professional encounter	99404	
PR0107	Professional encounter	99411	
PR0107	Professional encounter	99412	
PR0107	Professional encounter	99420	
PR0107	Professional encounter	99429	
PR0107	Professional encounter	S0270	
PR0107	Professional encounter	S0271	
PR0107	Professional encounter	S0272	
PR0107	Professional encounter	S0273	
	Code Set Description	Procedure Code	
PR0108	Professional supervision	99321	
PR0108	Professional supervision	99322	
PR0108	Professional supervision	99323	
PR0108	Professional supervision	99324	
PR0108	Professional supervision	99325	
PR0108	Professional supervision	99326	
PR0108	Professional supervision	99327	
PR0108	Professional supervision	99328	
PR0108	Professional supervision	99331	
PR0108	Professional supervision	99332	
PR0108	Professional supervision	99333	
PR0108	Professional supervision	99334	
PR0108	Professional supervision	99335	
PR0108	Professional supervision	99336	
PR0108	Professional supervision	99337	

	NQF #ACF	P-042-10
PR0108 Professional supervision 99339		
PR0108 Professional supervision 99340		
PR0108 Professional supervision 99371		
PR0108 Professional supervision 99372		
PR0108 Professional supervision 99373		
PR0108 Professional supervision 99374		
PR0108 Professional supervision 99375		
PR0108 Professional supervision 99377		
PR0108 Professional supervision 99378		
PR0108 Professional supervision 99379 PR0108 Professional supervision 99380		
PR0108 Professional supervision 99441		
PR0108 Professional supervision 99442		
PR0108 Professional supervision 99443		
PR0108 Professional supervision 99444		
PR0108 Professional supervision G0179		
PR0108 Professional supervision G0180		
PR0108 Professional supervision G0181		
PR0108 Professional supervision G0182		
Code Set Code Set Description Revenue Code		
RV0107 Professional encounter 0510		
RV0107 Professional encounter 0511		
RV0107 Professional encounter 0512		
RV0107 Professional encounter 0513		
RV0107 Professional encounter 0514		
RV0107 Professional encounter 0515		
RV0107 Professional encounter 0516		
RV0107 Professional encounter 0517		
RV0107 Professional encounter 0519		
RV0107 Professional encounter 0520		
RV0107 Professional encounter 0521		
RV0107 Professional encounter 0522 DV0107 Professional encounter 0523		
RV0107Professional encounter0523RV0107Professional encounter0524		
RV0107Professional encounter0524RV0107Professional encounter0525		
RV0107 Professional encounter 0525 RV0107 Professional encounter 0526		
RV0107 Professional encounter 0528		
RV0107 Professional encounter 0529		
RV0107 Professional encounter 0981		
RV0107 Professional encounter 0983		
ed set BV code set description		
cd. set RX code set description ndc RX-28 Butalbital-containing medication	00002065002	
RX-28 Butabital-containing medication	00002065002	
RX-28 Butalbital-containing medication	00002065102	
RX-28 Butalbital-containing medication	00002065103	
RX-28 Butalbital-containing medication	00002065133	
RX-28 Butalbital-containing medication	00002066702	
RX-28 Butalbital-containing medication	00002204202	
RX-28 Butalbital-containing medication	00002204203	
RX-28 Butalbital-containing medication	00002204902	
RX-28 Butalbital-containing medication	00002204903	
RX-28 Butalbital-containing medication	00002311202	
RX-28 Butalbital-containing medication	00002311203	
RX-28 Butalbital-containing medication	00002311302	
RX-28 Butalbital-containing medication	00002311303	
RX-28 Butalbital-containing medication	00002311333	

			NQF #ACP-042-10
RX-28	Butalbital-containing medication	00002311402	
RX-28	Butalbital-containing medication	00002406602	
RX-28	Butalbital-containing medication	00002406603	
RX-28	Butalbital-containing medication	00002406702	
RX-28	Butalbital-containing medication	00002406703	
RX-28	Butalbital-containing medication	00009068603	
RX-28	Butalbital-containing medication	00009071601	
RX-28	Butalbital-containing medication	00009071603	
RX-28	Butalbital-containing medication	00013130117	
RX-28	Butalbital-containing medication	00013130118	
RX-28	Butalbital-containing medication	00013130121	
RX-28	Butalbital-containing medication	00047004924	
RX-28	Butalbital-containing medication	00047004930	
RX-28	Butalbital-containing medication	00047010624	
RX-28	Butalbital-containing medication	00047011424	
RX-28	Butalbital-containing medication	00063128006	
RX-28	Butalbital-containing medication	00071079232	
RX-28 RX-28	Butalbital-containing medication	00071079332	
RX-28	Butalbital-containing medication Butalbital-containing medication	00071079340 00078008405	
RX-28	Butalbital-containing medication	00078008405	
RX-28	Butalbital-containing medication	00078008408	
RX-28	Butalbital-containing medication	00078008465	
RX-28	Butalbital-containing medication	00078010305	
RX-28	Butalbital-containing medication	00078010308	
RX-28	Butalbital-containing medication	00078010313	
RX-28	Butalbital-containing medication	00078010405	
RX-28	Butalbital-containing medication	00078010406	
RX-28	Butalbital-containing medication	00078010409	
RX-28	Butalbital-containing medication	00078010465	
RX-28	Butalbital-containing medication	00078010505	
RX-28	Butalbital-containing medication	00078010605	
RX-28	Butalbital-containing medication	00078010705	
RX-28	Butalbital-containing medication	00078010713	
RX-28	Butalbital-containing medication	00078010765	
RX-28	Butalbital-containing medication	00078024305	
RX-28	Butalbital-containing medication	00078024313	
RX-28 RX-28	Butalbital-containing medication	00081034355	
RX-28	Butalbital-containing medication Butalbital-containing medication	00081034375 00081035655	
RX-28	Butalbital-containing medication	00081035675	
RX-28	Butalbital-containing medication	00081036955	
RX-28	Butalbital-containing medication	00081036975	
RX-28	Butalbital-containing medication	00086005010	
RX-28	Butalbital-containing medication	00086005050	
RX-28	Butalbital-containing medication	00086005510	
RX-28	Butalbital-containing medication	00086005610	
RX-28	Butalbital-containing medication	00086005650	
RX-28	Butalbital-containing medication	00093057001	
RX-28	Butalbital-containing medication	00093057010	
RX-28	Butalbital-containing medication	00093085401	
RX-28	Butalbital-containing medication	00095024001	
RX-28	Butalbital-containing medication	00095024005	
RX-28	Butalbital-containing medication	00102220201	
RX-28	Butalbital-containing medication	00102220301	
RX-28	Butalbital-containing medication	00102307501	
RX-28	Butalbital-containing medication	00102373501	
RX-28	Butalbital-containing medication	00117130202	

			NQF #ACP-042-10
RX-28	Butalbital-containing medication	00117130205	
RX-28	Butalbital-containing medication	00117202802	
RX-28	Butalbital-containing medication	00117202805	
RX-28	Butalbital-containing medication	00117204202	
RX-28	Butalbital-containing medication	00117204205	
RX-28	Butalbital-containing medication	00143111501	
RX-28	Butalbital-containing medication	00143111505	
RX-28	Butalbital-containing medication	00143178501	
RX-28	Butalbital-containing medication	00143178510	
RX-28	Butalbital-containing medication	00143178525	
RX-28	Butalbital-containing medication	00143178530	
RX-28	Butalbital-containing medication	00143178552	
RX-28	Butalbital-containing medication	00143178701	
RX-28	Butalbital-containing medication	00143178705	
RX-28	Butalbital-containing medication	00143300001	
RX-28	Butalbital-containing medication	00150389160	
RX-28	Butalbital-containing medication	00150389180	
RX-28	Butalbital-containing medication	00157043101	
RX-28	Butalbital-containing medication	00157043110	
RX-28	Butalbital-containing medication	00157074901	
RX-28	Butalbital-containing medication	00157074905	
RX-28	Butalbital-containing medication	00166034303	
RX-28	Butalbital-containing medication	00166034306	
RX-28	Butalbital-containing medication	00166088015	
RX-28	Butalbital-containing medication	00166088111	
RX-28	Butalbital-containing medication	00166088115	
RX-28	Butalbital-containing medication	00172399660	
RX-28	Butalbital-containing medication	00172399680	
RX-28	Butalbital-containing medication	00172480260	
RX-28	Butalbital-containing medication	00172480270	
RX-28	Butalbital-containing medication	00182003601	
RX-28	Butalbital-containing medication	00182014001	
RX-28 RX-28	Butalbital-containing medication Butalbital-containing medication	00182127401	
RX-28	Butalbital-containing medication	00182127405 00182156205	
RX-28	Butalbital-containing medication	00182163101	
RX-28	Butalbital-containing medication	00182163101	
RX-20	Butalbital-containing medication	00182173401	
RX-28	Butalbital-containing medication	00182173410	
RX-28	Butalbital-containing medication	00182265901	
RX-28	Butalbital-containing medication	00182265905	
RX-28	Butalbital-containing medication	00182269301	
RX-28	Butalbital-containing medication	00182269401	
RX-28	Butalbital-containing medication	00184021260	
RX-28	Butalbital-containing medication	00187084201	
RX-28	Butalbital-containing medication	00187084301	
RX-28	Butalbital-containing medication	00187084401	
RX-28	Butalbital-containing medication	00217281101	
RX-28	Butalbital-containing medication	00217281103	
RX-28		00228202310	
RX-28	Butalbital-containing medication	00228202396	
RX-28	Butalbital-containing medication	00228202510	
RX-28	Butalbital-containing medication	00228209510	
RX-28	Butalbital-containing medication	00247018505	
RX-28	Butalbital-containing medication	00247018510	
RX-28	Butalbital-containing medication	00247018512	
RX-28	Butalbital-containing medication	00247018520	
RX-28	Butalbital-containing medication	00247018524	

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable

			NQF #ACP-042-10
RX-28	Butalbital-containing medication	00247018525	
RX-28	Butalbital-containing medication	00247018530	
RX-28	Butalbital-containing medication	00247021400	
RX-28	Butalbital-containing medication	00247021406	
RX-28	Butalbital-containing medication	00247021409	
RX-28	Butalbital-containing medication	00247021412	
RX-28	Butalbital-containing medication	00247021415	
RX-28	Butalbital-containing medication	00247021420	
RX-28	Butalbital-containing medication	00247021425	
RX-28	Butalbital-containing medication	00247021428	
RX-28	Butalbital-containing medication	00247021430	
RX-28	Butalbital-containing medication	00247033700	
RX-28	Butalbital-containing medication	00247033706	
RX-28	Butalbital-containing medication	00247033710	
RX-28	Butalbital-containing medication	00247033712	
RX-28	Butalbital-containing medication	00247033715	
RX-28	Butalbital-containing medication	00247033716	
RX-28	Butalbital-containing medication	00247033720	
RX-28	Butalbital-containing medication	00247033724	
RX-28	Butalbital-containing medication	00247033725	
RX-28	Butalbital-containing medication	00247033730	
RX-28	Butalbital-containing medication	00247033750	
RX-28	Butalbital-containing medication	00247084520	
RX-28	Butalbital-containing medication	00247084525	
RX-28	Butalbital-containing medication	00247105320	
RX-28	Butalbital-containing medication	00247105324	
RX-28	Butalbital-containing medication	00247105330	
RX-28	Butalbital-containing medication	00258365701	
RX-28	Butalbital-containing medication	00258366501	
RX-28	Butalbital-containing medication	00258366505	
RX-28	Butalbital-containing medication	00259036201	
RX-28	Butalbital-containing medication	00259039201	
RX-28	Butalbital-containing medication	00259125601	
RX-28	Butalbital-containing medication	00259127801	
RX-28	Butalbital-containing medication	00259225601	
RX-28	Butalbital-containing medication	00259329001	
RX-28	Butalbital-containing medication	00281019817	
RX-28	Butalbital-containing medication	00281038953	
RX-28	Butalbital-containing medication	00281130117	
RX-28	Butalbital-containing medication	00298297511	
RX-28	Butalbital-containing medication	00298298505	
RX-28 RX-28	Butalbital-containing medication Butalbital-containing medication	00302028701 00302049001	
	•		
RX-28 RX-28	Butalbital-containing medication Butalbital-containing medication	00302049005	
RX-28 RX-28	Butalbital-containing medication	00302353010	
RX-20 RX-28	Butalbital-containing medication	00302353501 00302353510	
RX-28	Butalbital-containing medication	00304016100	
RX-28	Butalbital-containing medication	00304016101	
RX-20	Butalbital-containing medication	00304016111	
RX-20	Butalbital-containing medication	00304016200	
RX-28	Butalbital-containing medication	00304116401	
RX-28	Butalbital-containing medication	00304116405	
RX-20	Butalbital-containing medication	00304166201	
RX-20	Butalbital-containing medication	00304194001	
RX-20	Butalbital-containing medication	00304194005	
RX-20	Butalbital-containing medication	00304194003	
RX-28	Butalbital-containing medication	00304196901	
	Satalortar containing modication	00001170701	

			NQF #ACP-042-10
RX-28	Butalbital-containing medication	00304196905	
RX-28	Butalbital-containing medication	00306251080	
RX-28	Butalbital-containing medication	00306251085	
RX-28	Butalbital-containing medication	00306289080	
RX-28	Butalbital-containing medication	00306289090	
RX-28	Butalbital-containing medication	00306289590	
RX-28	Butalbital-containing medication	00314222901	
RX-28	Butalbital-containing medication	00314222910	
RX-28	Butalbital-containing medication	00339406312	
RX-28	Butalbital-containing medication	00339584312	
RX-28	Butalbital-containing medication	00349829901	
RX-28	Butalbital-containing medication	00349829910	
RX-28	Butalbital-containing medication	00349830101	
RX-28	Butalbital-containing medication	00349830105	
RX-28	Butalbital-containing medication	00349835201	
RX-28	Butalbital-containing medication	00349835210	
RX-28	Butalbital-containing medication	00349879301	
RX-28	Butalbital-containing medication	00349879305	
RX-28	Butalbital-containing medication	00349879310	
RX-28	Butalbital-containing medication	00359050610	
RX-28	Butalbital-containing medication	00359050640	
RX-28	Butalbital-containing medication	00359050710	
RX-28	Butalbital-containing medication	00359050740	
RX-28	Butalbital-containing medication	00359054450	
RX-28	Butalbital-containing medication	00359054550	
RX-28	Butalbital-containing medication	00364057202	
RX-28	Butalbital-containing medication	00364065601	
RX-28	Butalbital-containing medication	00364067701	
RX-28	Butalbital-containing medication	00364067702	
RX-28	Butalbital-containing medication	00364072601	
RX-28	Butalbital-containing medication	00364072602	
RX-28	Butalbital-containing medication	00364229701	
RX-28	Butalbital-containing medication	00364229705	
RX-28	Butalbital-containing medication	00364233901	
RX-28 RX-28	Butalbital-containing medication	00367202310	
RX-28 RX-28	Butalbital-containing medication	00403089130	
RX-28	Butalbital-containing medication Butalbital-containing medication	00403089140	
RX-28	Butalbital-containing medication	00403089220 00403089230	
RX-28	Butalbital-containing medication	00403089230	
RX-28	Butalbital-containing medication	00403363915	
RX-28	Butalbital-containing medication	00403363930	
RX-28	Butalbital-containing medication	00405002601	
RX-28	Butalbital-containing medication	00405002602	
RX-28	Butalbital-containing medication	00405002801	
RX-28	Butalbital-containing medication	00405002901	
RX-28	Butalbital-containing medication	00406097001	
RX-28	Butalbital-containing medication	00406097005	
RX-28	Butalbital-containing medication	00436014601	
RX-28	Butalbital-containing medication	00436014610	
RX-28	Butalbital-containing medication	00440720510	
RX-28	Butalbital-containing medication	00440720518	
RX-28	Butalbital-containing medication	00440720520	
RX-28	Butalbital-containing medication	00440720530	
RX-28	Butalbital-containing medication	00440720560	
RX-28	Butalbital-containing medication	00440721010	
RX-28	Butalbital-containing medication	00440721018	
RX-28	Butalbital-containing medication	00440721030	
	5		

			NQF #ACP-042-10
RX-28	Butalbital-containing medication	00440721130	
RX-28	Butalbital-containing medication	00456054601	
RX-28	Butalbital-containing medication	00456054602	
RX-28	Butalbital-containing medication	00456063001	
RX-28	Butalbital-containing medication	00456063002	
RX-28	Butalbital-containing medication	00456063101	
RX-28	Butalbital-containing medication	00456067701	
RX-28	Butalbital-containing medication	00456067801	
RX-28	Butalbital-containing medication	00456067802	
RX-28	Butalbital-containing medication	00456067901	
RX-28	Butalbital-containing medication	00456067902	
RX-28	Butalbital-containing medication	00525090301	
RX-28	Butalbital-containing medication	00527104310	
RX-28	Butalbital-containing medication	00527114510	
RX-28	Butalbital-containing medication	00527131201	
RX-28	Butalbital-containing medication	00527155201	
RX-28	Butalbital-containing medication	00527155210	
RX-28	Butalbital-containing medication	00535001101	
RX-28	Butalbital-containing medication	00535001102	
RX-28	Butalbital-containing medication	00535001201	
RX-28	Butalbital-containing medication	00536324010	
RX-28	Butalbital-containing medication	00536324050	
RX-28	Butalbital-containing medication	00536324410	
RX-28	Butalbital-containing medication	00536324450	
RX-28	Butalbital-containing medication	00536324810	
RX-28	Butalbital-containing medication	00536325010	
RX-28	Butalbital-containing medication	00536392401	
RX-28	Butalbital-containing medication	00536392410	
RX-28	Butalbital-containing medication	00536392501	
RX-28	Butalbital-containing medication	00536392505	
RX-28	Butalbital-containing medication	00536393301	
RX-28	Butalbital-containing medication	00536393310	
RX-28	Butalbital-containing medication	00536393701	
RX-28	Butalbital-containing medication	00536393710	
RX-28	Butalbital-containing medication	00536394201	
RX-28	Butalbital-containing medication	00536394205	
RX-28 RX-28	Butalbital-containing medication	00536394210	
RX-20 RX-28	Butalbital-containing medication	00536395101	
RX-20	Butalbital-containing medication Butalbital-containing medication	00536423901 00536485601	
RX-28	Butalbital-containing medication	00536485610	
RX-28	Butalbital-containing medication	00536556701	
RX-28	Butalbital-containing medication	00536556705	
RX-28	Butalbital-containing medication	00536556710	
RX-28	Butalbital-containing medication	00536575401	
RX-28	Butalbital-containing medication	00537105401	
RX-28	Butalbital-containing medication	00537105410	
RX-28	Butalbital-containing medication	00537203610	
RX-28	Butalbital-containing medication	00537657501	
RX-28	Butalbital-containing medication	00537657510	
RX-28	Butalbital-containing medication	00538300101	
RX-28	Butalbital-containing medication	00538328101	
RX-28	Butalbital-containing medication	00538328301	
RX-28	Butalbital-containing medication	00538328305	
RX-28	Butalbital-containing medication	00538328401	
RX-28	Butalbital-containing medication	00539090601	
RX-28	Butalbital-containing medication	00551018101	
RX-28	Butalbital-containing medication	00580003910	

			NQF #ACP-042-10
RX-28	Butalbital-containing medication	00580072001	
RX-28	Butalbital-containing medication	00580072010	
RX-28	Butalbital-containing medication	00580139905	
RX-28	Butalbital-containing medication	00580162201	
RX-28	Butalbital-containing medication	00580171701	
RX-28	Butalbital-containing medication	00588777701	
RX-28	Butalbital-containing medication	00588778801	
RX-28	Butalbital-containing medication	00591042501	
RX-28	Butalbital-containing medication	00591042505	
RX-28	Butalbital-containing medication	00591048501	
RX-28	Butalbital-containing medication	00591048505	
RX-28	Butalbital-containing medication	00591321901	
RX-28	Butalbital-containing medication	00591322001	
RX-28	Butalbital-containing medication	00591336901	
RX-28	Butalbital-containing medication	00591336905	
RX-28	Butalbital-containing medication	00591341601	
RX-28	Butalbital-containing medication	00591341605	
RX-28	Butalbital-containing medication	00591354601	
RX-28	Butalbital-containing medication	00591354605	
RX-28	Butalbital-containing medication	00603254021	
RX-28	Butalbital-containing medication	00603254221	
RX-28 RX-28	Butalbital-containing medication Butalbital-containing medication	00603254421	
RX-20 RX-28	Butalbital-containing medication	00603254428 00603254432	
RX-20	Butalbital-containing medication	00603254432	
RX-28	Butalbital-containing medication	00603254528	
RX-28	Butalbital-containing medication	00603254621	
RX-28	Butalbital-containing medication	00603254721	
RX-28	Butalbital-containing medication	00603254728	
RX-28	Butalbital-containing medication	00603254821	
RX-28	Butalbital-containing medication	00603254832	
RX-28	Butalbital-containing medication	00603254921	
RX-28	Butalbital-containing medication	00603254928	
RX-28	Butalbital-containing medication	00603255021	
RX-28	Butalbital-containing medication	00603255121	
RX-28	Butalbital-containing medication	00603255221	
RX-28	Butalbital-containing medication	00603255321	
RX-28	Butalbital-containing medication	00615044801	
RX-28	Butalbital-containing medication	00615044901	
RX-28	Butalbital-containing medication	00615044910	
RX-28	Butalbital-containing medication	00642016210	
RX-28	Butalbital-containing medication	00642016410	
RX-28	Butalbital-containing medication	00642016610	
RX-28	Butalbital-containing medication	00642713210	
RX-28	Butalbital-containing medication	00677082701	
RX-28	Butalbital-containing medication	00677082710	
RX-28	Butalbital-containing medication	00677084401	
RX-28	Butalbital-containing medication	00677124201	
RX-28 RX-28	Butalbital-containing medication Butalbital-containing medication	00677124205 00677143901	
RX-20 RX-28	Butalbital-containing medication	00677173801	
RX-20	Butalbital-containing medication	00677174801	
RX-28	Butalbital-containing medication	00677174805	
RX-28	Butalbital-containing medication	00682080301	
RX-28	Butalbital-containing medication	00682080401	
RX-28	Butalbital-containing medication	00682140001	
RX-28	Butalbital-containing medication	00716082401	
RX-28	Butalbital-containing medication	00716082410	
	5		

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable

			NQF #ACP-042	2-10
RX-28	Butalbital-containing medication	00719039010		
RX-28	Butalbital-containing medication	00719041010		
RX-28	Butalbital-containing medication	00719041013		
RX-28	Butalbital-containing medication	00719042013		
RX-28	Butalbital-containing medication	00719042110		
RX-28	Butalbital-containing medication	00719042113		
RX-28	Butalbital-containing medication	00719118610		
RX-28	Butalbital-containing medication	00719118612		
RX-28	Butalbital-containing medication	00729085210		
RX-28	Butalbital-containing medication	00779061325		
RX-28	Butalbital-containing medication	00779061330		
RX-28	Butalbital-containing medication	00779061425		
RX-28	Butalbital-containing medication	00779061430		
RX-28	Butalbital-containing medication	00779061527		
RX-28	Butalbital-containing medication	00781143501		
RX-28	Butalbital-containing medication	00781143510		
RX-28 RX-28	Butalbital-containing medication	00781190101		
RX-28	Butalbital-containing medication	00781191801 00781191805		
RX-28	Butalbital-containing medication Butalbital-containing medication	00781212001		
RX-28	Butalbital-containing medication	00781221001		
RX-28	Butalbital-containing medication	00781222101		
RX-28	Butalbital-containing medication	00785230501		
RX-28	Butalbital-containing medication	00785230701		
RX-28	Butalbital-containing medication	00814381914		
RX-28	Butalbital-containing medication	00814381930		
RX-28	Butalbital-containing medication	00814382014		
RX-28	Butalbital-containing medication	00814382028		
RX-28	Butalbital-containing medication	00814382214		
RX-28	Butalbital-containing medication	00814382230		
RX-28	Butalbital-containing medication	00814382414		
RX-28	Butalbital-containing medication	00814382428		
RX-28	Butalbital-containing medication	00814382514		
RX-28 RX-28	Butalbital-containing medication	00822043010		
RX-28	Butalbital-containing medication Butalbital-containing medication	00822043025 00822043210		
RX-28	Butalbital-containing medication	00822043210		
RX-28	Butalbital-containing medication	00822043223		
RX-28	Butalbital-containing medication	00822043325		
RX-28	Butalbital-containing medication	00839133320		
RX-28	Butalbital-containing medication	00839500220		
RX-28	Butalbital-containing medication	00839668906		
RX-28	Butalbital-containing medication	00839668912		
RX-28	Butalbital-containing medication	00839668916		
RX-28	Butalbital-containing medication	00839673306		
RX-28	Butalbital-containing medication	00839673316		
RX-28	Butalbital-containing medication	00839704706		
RX-28	Butalbital-containing medication	00839704716		
RX-28	Butalbital-containing medication	00839748006		
RX-28 RX-28	Butalbital-containing medication Butalbital-containing medication	00839748012 00839783106		
RX-28 RX-28	Butalbital-containing medication	00839783106		
RX-20 RX-28	Butalbital-containing medication	00879054301		
RX-28	Butalbital-containing medication	00879054305		
RX-28	Butalbital-containing medication	00879056601		
RX-28	Butalbital-containing medication	00879056610		
RX-28	Butalbital-containing medication	00879056701		
RX-28	Butalbital-containing medication	00879056705		

			NQF #ACP-042-10
RX-28	Butalbital-containing medication	00879056710	
RX-28	Butalbital-containing medication	00879064701	
RX-28	Butalbital-containing medication	00879064705	
RX-28	Butalbital-containing medication	00879064801	
RX-28	Butalbital-containing medication	00879064805	
RX-28	Butalbital-containing medication	00904042540	
RX-28	Butalbital-containing medication	00904042560	
RX-28	Butalbital-containing medication	00904328040	
RX-28	Butalbital-containing medication	00904328060	
RX-28	Butalbital-containing medication	00904328061	
RX-28	Butalbital-containing medication	00904329340	
RX-28	Butalbital-containing medication	00904329360	
RX-28	Butalbital-containing medication	00904389160	
RX-28	Butalbital-containing medication	00904389180	
RX-28	Butalbital-containing medication	00904389260	
RX-28	Butalbital-containing medication	00904389280	
RX-28	Butalbital-containing medication	00904393240	
RX-28	Butalbital-containing medication	00904393260	
RX-28	Butalbital-containing medication	00904393460	
RX-28	Butalbital-containing medication	00904393640	
RX-28	Butalbital-containing medication	00904393660	
RX-28	Butalbital-containing medication	00904393740	
RX-28	Butalbital-containing medication	00904393760	
RX-28	Butalbital-containing medication	00904514060	
RX-28 RX-28	Butalbital-containing medication	00904549060	
RX-28 RX-28	Butalbital-containing medication	00948529710	
RX-28 RX-28	Butalbital-containing medication Butalbital-containing medication	00948559801 10544035330	
RX-20	Butalbital-containing medication	10892011610	
RX-28	Butalbital-containing medication	11311095401	
RX-28	Butalbital-containing medication	11311095501	
RX-28	Butalbital-containing medication	11311095601	
RX-28	Butalbital-containing medication	11584002901	
RX-28	Butalbital-containing medication	11584102901	
RX-28	Butalbital-containing medication	11735040011	
RX-28	Butalbital-containing medication	11735099911	
RX-28	Butalbital-containing medication	11845012301	
RX-28	Butalbital-containing medication	11845012303	
RX-28	Butalbital-containing medication	11845023901	
RX-28	Butalbital-containing medication	11845023904	
RX-28	Butalbital-containing medication	11845023910	
RX-28	Butalbital-containing medication	11845024001	
RX-28	Butalbital-containing medication	11845024003	
RX-28	Butalbital-containing medication	12071000601	
RX-28	Butalbital-containing medication	12071000605	
RX-28	Butalbital-containing medication	12071040910	
RX-28	Butalbital-containing medication	12071041101	
RX-28	Butalbital-containing medication	12071041110	
	Butalbital-containing medication	12939081112	
RX-28	Butalbital-containing medication	12939081150	
RX-28	Butalbital-containing medication	12939081212	
RX-28	Butalbital-containing medication	12939081213	
RX-28	Butalbital-containing medication	16590002220	
RX-28	Butalbital-containing medication	16590002230	
RX-28	Butalbital-containing medication	16590002260	
RX-28	Butalbital-containing medication Butalbital-containing medication	16590002272	
RX-28 RX-28	Butalbital-containing medication Butalbital-containing medication	16590002290 16590035120	
πл-20	butaibitai-contaitiing medication	10370033120	

			NQF #ACP-042-10
RX-28	Butalbital-containing medication	16590035130	
RX-28	Butalbital-containing medication	16590035160	
RX-28	Butalbital-containing medication	16590035172	
RX-28	Butalbital-containing medication	16590035190	
RX-28	Butalbital-containing medication	16590047020	
RX-28	Butalbital-containing medication	16590047030	
RX-28	Butalbital-containing medication	16590047060	
RX-28	Butalbital-containing medication	16590047090	
RX-28	Butalbital-containing medication	17022105706	
RX-28	Butalbital-containing medication	17236010610	
RX-28	Butalbital-containing medication	17236010801	
RX-28	Butalbital-containing medication	17236010810	
RX-28	Butalbital-containing medication	17236015901	
RX-28	Butalbital-containing medication	17236015905	
RX-28	Butalbital-containing medication	17236016501	
RX-28	Butalbital-containing medication	17236016510	
RX-28	Butalbital-containing medication	17236045901	
RX-28	Butalbital-containing medication	17236045905	
RX-28	Butalbital-containing medication	17236049401	
RX-28 RX-28	Butalbital-containing medication	18837001760	
RX-28	Butalbital-containing medication	18837033360 18837033390	
RX-28	Butalbital-containing medication Butalbital-containing medication	21695020920	
RX-28	Butalbital-containing medication	21695020920	
RX-28	Butalbital-containing medication	21695020960	
RX-28	Butalbital-containing medication	21695020972	
RX-28	Butalbital-containing medication	21695025708	
RX-28	Butalbital-containing medication	21695025728	
RX-28	Butalbital-containing medication	21695025730	
RX-28	Butalbital-containing medication	21695025760	
RX-28	Butalbital-containing medication	21695025828	
RX-28	Butalbital-containing medication	21695025830	
RX-28	Butalbital-containing medication	21695025860	
RX-28	Butalbital-containing medication	21695035460	
RX-28	Butalbital-containing medication	23490518201	
RX-28	Butalbital-containing medication	23490518301	
RX-28	Butalbital-containing medication	23490518302	
RX-28	Butalbital-containing medication	23490518303	
RX-28	Butalbital-containing medication	23490518306	
RX-28	Butalbital-containing medication	23490518309	
RX-28	Butalbital-containing medication	23490682503	
RX-28 RX-28	Butalbital-containing medication	23490786700 23490786703	
RX-28	Butalbital-containing medication Butalbital-containing medication	23490786706	
RX-28	Butalbital-containing medication	24208000301	
RX-28	Butalbital-containing medication	24208000310	
RX-28	Butalbital-containing medication	24208000310	
RX-28	Butalbital-containing medication	31190008801	
RX-28	Butalbital-containing medication	33358005830	
RX-28	Butalbital-containing medication	33358005920	
RX-28	Butalbital-containing medication	33358005930	
RX-28	Butalbital-containing medication	33358005960	
RX-28	Butalbital-containing medication	33358006030	
RX-28	Butalbital-containing medication	33358006130	
RX-28	Butalbital-containing medication	33358006190	
RX-28	Butalbital-containing medication	35356000500	
RX-28	Butalbital-containing medication	35470001401	
RX-28	Butalbital-containing medication	35470037501	

			NQF #ACP-042-10
RX-28	Butalbital-containing medication	35470389101	
RX-28	Butalbital-containing medication	35470389109	
RX-28	Butalbital-containing medication	35470390001	
RX-28	Butalbital-containing medication	38130011101	
RX-28	Butalbital-containing medication	38130032501	
RX-28	Butalbital-containing medication	42549055330	
RX-28	Butalbital-containing medication	43353027530	
RX-28	Butalbital-containing medication	43353027553	
RX-28	Butalbital-containing medication	43353027560	
RX-28	Butalbital-containing medication	43353027570	
RX-28	Butalbital-containing medication	43797007203	
RX-28	Butalbital-containing medication	43797024403	
RX-28	Butalbital-containing medication	43797024405	
RX-28	Butalbital-containing medication	43797024406	
RX-28	Butalbital-containing medication	43797024503	
RX-28	Butalbital-containing medication	43797034303	
RX-28	Butalbital-containing medication	43797034305	
RX-28	Butalbital-containing medication	43797034306	
RX-28	Butalbital-containing medication	44437034301	
RX-28	Butalbital-containing medication	44514008818	
RX-28	Butalbital-containing medication	45985057801	
RX-28	Butalbital-containing medication	46672005310	
RX-28	Butalbital-containing medication	46672005350	
RX-28	Butalbital-containing medication	47202201201	
RX-28	Butalbital-containing medication	47202201203	
RX-28	Butalbital-containing medication	47202201301	
RX-28	Butalbital-containing medication	47202201303	
RX-28	Butalbital-containing medication	47202248201	
RX-28	Butalbital-containing medication	47202248202	
RX-28	Butalbital-containing medication	47202257601	
RX-28	Butalbital-containing medication	47202260801	
RX-28 RX-28	Butalbital-containing medication Butalbital-containing medication	47202260802 47202289401	
RX-28	Butalbital-containing medication	47202289401	
RX-20	Butalbital-containing medication	47649024405	
RX-28	Butalbital-containing medication	47649037010	
RX-28	Butalbital-containing medication	47649056010	
RX-28	Butalbital-containing medication	47679052001	
RX-28	Butalbital-containing medication	47679052035	
RX-28	Butalbital-containing medication	47679053001	
RX-28	Butalbital-containing medication	47679053004	
RX-28	Butalbital-containing medication	47679053035	
RX-28	Butalbital-containing medication	47679053065	
RX-28	Butalbital-containing medication	48253015101	
RX-28	Butalbital-containing medication	48534088411	
RX-28	Butalbital-containing medication	49335106401	
RX-28	Butalbital-containing medication	49335106402	
RX-28	Butalbital-containing medication	49335202801	
RX-28	Butalbital-containing medication	49335202802	
RX-28	Butalbital-containing medication	49648016100	
RX-28	Butalbital-containing medication	49648016101	
RX-28	Butalbital-containing medication	49648016200	
RX-28	Butalbital-containing medication	49648116401	
RX-28	Butalbital-containing medication	49648116405	
RX-28	Butalbital-containing medication	49648166201	
RX-28	Butalbital-containing medication	49727019302	
RX-28	Butalbital-containing medication	49727019304	
RX-28	Butalbital-containing medication	49727019305	

			NQF #ACP-042-10
RX-28	Butalbital-containing medication	49727019702	
RX-28	Butalbital-containing medication	49727019705	
RX-28	Butalbital-containing medication	49884081101	
RX-28	Butalbital-containing medication	49884081105	
RX-28	Butalbital-containing medication	49999011520	
RX-28	Butalbital-containing medication	49999011530	
RX-28	Butalbital-containing medication	49999011560	
RX-28	Butalbital-containing medication	49999015120	
RX-28	Butalbital-containing medication	49999015130	
RX-28	Butalbital-containing medication	49999015160	
RX-28	Butalbital-containing medication	50272089901	
RX-28	Butalbital-containing medication	50272089903	
RX-28	Butalbital-containing medication	50430004903	
RX-28	Butalbital-containing medication	50430004906	
RX-28	Butalbital-containing medication	50474070101	
RX-28	Butalbital-containing medication	50474070201	
RX-28	Butalbital-containing medication	50474070301	
RX-28	Butalbital-containing medication	50564011101	
RX-28	Butalbital-containing medication	50564050701	
RX-28	Butalbital-containing medication	50564050705	
RX-28	Butalbital-containing medication	50752027505	
RX-28	Butalbital-containing medication	50752027508	
RX-28	Butalbital-containing medication	50752027705	
RX-28	Butalbital-containing medication	50752027709	
RX-28	Butalbital-containing medication	50752027805	
RX-28	Butalbital-containing medication	50752027905	
RX-28	Butalbital-containing medication	50991030001	
RX-28	Butalbital-containing medication	50991030201	
RX-28	Butalbital-containing medication	50991051416	
RX-28	Butalbital-containing medication	51189008601	
RX-28	Butalbital-containing medication	51285068402	
RX-28	Butalbital-containing medication	51285068404	
RX-28	Butalbital-containing medication	51285084902	
RX-28	Butalbital-containing medication	51285084904	
RX-28	Butalbital-containing medication	51285090802	
RX-28	Butalbital-containing medication	51432003106	
RX-28	Butalbital-containing medication	51432003200	
RX-28	Butalbital-containing medication	51432003203	
RX-28	Butalbital-containing medication	51432003206	
RX-28	Butalbital-containing medication	51432003403	
RX-28 RX-28	Butalbital-containing medication	51432003405	
RX-28 RX-28	Butalbital-containing medication Butalbital-containing medication	51432003703 51432083803	
RX-20 RX-28	Butalbital-containing medication	51432083805	
RX-20	Butalbital-containing medication	51432903203	
RX-20	Butalbital-containing medication	51432903205	
RX-20 RX-28	Butalbital-containing medication	51452905200	
RX-28	Butalbital-containing medication	51655080954	
RX-28	Butalbital-containing medication	51674000901	
RX-28	Butalbital-containing medication	51728017801	
RX-28	Butalbital-containing medication	51728017810	
RX-28	Butalbital-containing medication	51728017910	
RX-28	Butalbital-containing medication	51728054701	
RX-28	Butalbital-containing medication	51728054705	
RX-28	Butalbital-containing medication	51991007301	
RX-28	Butalbital-containing medication	51991007401	
RX-28	Butalbital-containing medication	51991007405	
RX-28	Butalbital-containing medication	51991033301	
	g incarcation		

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable

			NQF #ACP-042-10
RX-28	Butalbital-containing medication	51991033305	
RX-28	Butalbital-containing medication	52406091501	
RX-28	Butalbital-containing medication	52406091510	
RX-28	Butalbital-containing medication	52406091610	
RX-28	Butalbital-containing medication	52406091701	
RX-28	Butalbital-containing medication	52446000221	
RX-28	Butalbital-containing medication	52446006721	
RX-28	Butalbital-containing medication	52446006732	
RX-28	Butalbital-containing medication	52446007221	
RX-28	Butalbital-containing medication	52446054421	
RX-28	Butalbital-containing medication	52446054428	
RX-28	Butalbital-containing medication	52493012601	
RX-28	Butalbital-containing medication	52493012620	
RX-28	Butalbital-containing medication	52493012630	
RX-28	Butalbital-containing medication	52493012650	
RX-28	Butalbital-containing medication	52544042501	
RX-28	Butalbital-containing medication	52544042505	
RX-28	Butalbital-containing medication	52544048501	
RX-28	Butalbital-containing medication	52544048505	
RX-28	Butalbital-containing medication	52544061301	
RX-28	Butalbital-containing medication	52544061305	
RX-28	Butalbital-containing medication	52544095501	
RX-28	Butalbital-containing medication	52544095601	
RX-28	Butalbital-containing medication	52544095701	
RX-28	Butalbital-containing medication	52544095705	
RX-28	Butalbital-containing medication	52544095801	
RX-28	Butalbital-containing medication	52555007901	
RX-28	Butalbital-containing medication	52555064701	
RX-28 RX-28	Butalbital-containing medication	52555064705	
_	Butalbital-containing medication	52728003694	
RX-28 RX-28	Butalbital-containing medication	52728015495	
RX-28	Butalbital-containing medication Butalbital-containing medication	52728049625 52747021260	
RX-28	Butalbital-containing medication	52747031160	
RX-28	Butalbital-containing medication	52747060060	
RX-28	Butalbital-containing medication	52765137600	
RX-28	Butalbital-containing medication	52803011101	
RX-28	Butalbital-containing medication	52803011104	
RX-28	Butalbital-containing medication	52803012701	
RX-28	Butalbital-containing medication	52959011915	
RX-28	Butalbital-containing medication	52959011930	
RX-28	Butalbital-containing medication	52959037000	
RX-28	Butalbital-containing medication	52959037012	
RX-28	Butalbital-containing medication	52959037020	
RX-28	Butalbital-containing medication	52959037025	
RX-28	Butalbital-containing medication	52959037030	
RX-28	Butalbital-containing medication	52959037050	
RX-28	Butalbital-containing medication	52959037060	
RX-28	Butalbital-containing medication	52959037090	
RX-28	Butalbital-containing medication	52959039900	
RX-28	Butalbital-containing medication	52959039920	
RX-28	Butalbital-containing medication	52959039930	
RX-28	Butalbital-containing medication	52959039950	
RX-28	Butalbital-containing medication	52959039960	
RX-28	Butalbital-containing medication	52959039990	
RX-28	Butalbital-containing medication	52959076730	
RX-28	Butalbital-containing medication	52959076760	
RX-28	Butalbital-containing medication	52959086500	

			NQF #ACP-042-10
RX-28	Butalbital-containing medication	52959086530	
RX-28	Butalbital-containing medication	52959091260	
RX-28	Butalbital-containing medication	52959091302	
RX-28	Butalbital-containing medication	52959091330	
RX-28	Butalbital-containing medication	53002011420	
RX-28	Butalbital-containing medication	53002011430	
RX-28	Butalbital-containing medication	53002013112	
RX-28	Butalbital-containing medication	53002013120	
RX-28	Butalbital-containing medication	53002013130	
RX-28	Butalbital-containing medication	53002013140	
RX-28	Butalbital-containing medication	53002060320	
RX-28	Butalbital-containing medication	53002104902	
RX-28	Butalbital-containing medication	53002104920	
RX-28	Butalbital-containing medication	53258060001	
RX-28 RX-28	Butalbital-containing medication Butalbital-containing medication	53258060013 53261054330	
RX-28	Butalbital-containing medication	53265023510	
RX-28	Butalbital-containing medication	53265023550	
RX-28	Butalbital-containing medication	53265023610	
RX-28	Butalbital-containing medication	53265023650	
RX-28	Butalbital-containing medication	53265024010	
RX-28	Butalbital-containing medication	53265024050	
RX-28	Butalbital-containing medication	53506015024	
RX-28	Butalbital-containing medication	53506015030	
RX-28	Butalbital-containing medication	53506016024	
RX-28	Butalbital-containing medication	53506016030	
RX-28	Butalbital-containing medication	54092017801	
RX-28	Butalbital-containing medication	54092017805	
RX-28	Butalbital-containing medication	54124005060	
RX-28	Butalbital-containing medication	54124005630	
RX-28	Butalbital-containing medication	54124008415	
RX-28	Butalbital-containing medication	54124008424	
RX-28	Butalbital-containing medication	54124033630	
RX-28	Butalbital-containing medication	54124046830	
RX-28 RX-28	Butalbital-containing medication Butalbital-containing medication	54274028510 54274035610	
RX-28	Butalbital-containing medication	54274035630	
RX-28	Butalbital-containing medication	54274035050	
RX-28	Butalbital-containing medication	54274036030	
RX-28	Butalbital-containing medication	54274036310	
RX-28	Butalbital-containing medication	54274036350	
RX-28	Butalbital-containing medication	54274079310	
RX-28	Butalbital-containing medication	54274079330	
RX-28	Butalbital-containing medication	54569001200	
RX-28	Butalbital-containing medication	54569001201	
RX-28	Butalbital-containing medication	54569001202	
RX-28	Butalbital-containing medication	54569001203	
RX-28	Butalbital-containing medication	54569001204	
RX-28	Butalbital-containing medication	54569001210	
RX-28	Butalbital-containing medication	54569001300	
RX-28	Butalbital-containing medication	54569001301	
RX-28	Butalbital-containing medication	54569001302 54560001202	
RX-28 RX-28	Butalbital-containing medication Butalbital-containing medication	54569001303 54560001217	
RX-28 RX-28	Butalbital-containing medication	54569001317 54569033700	
RX-20	Butalbital-containing medication	54569033701	
RX-28	Butalbital-containing medication	54569033702	
RX-28	Butalbital-containing medication	54569033703	

25

			NQF #ACP-042-10
RX-28	Butalbital-containing medication	54569033704	
RX-28	Butalbital-containing medication	54569033705	
RX-28	Butalbital-containing medication	54569033714	
RX-28	Butalbital-containing medication	54569033900	
RX-28	Butalbital-containing medication	54569033901	
RX-28	Butalbital-containing medication	54569033902	
RX-28	Butalbital-containing medication	54569033903	
RX-28	Butalbital-containing medication	54569033904	
RX-28	Butalbital-containing medication	54569033905	
RX-28	Butalbital-containing medication	54569033906	
RX-28	Butalbital-containing medication	54569033907	
RX-28	Butalbital-containing medication	54569033914	
RX-28	Butalbital-containing medication	54569034000	
RX-28	Butalbital-containing medication	54569034001	
RX-28	Butalbital-containing medication	54569034002	
RX-28	Butalbital-containing medication	54569034014	
RX-28	Butalbital-containing medication	54569034100	
RX-28	Butalbital-containing medication	54569034101	
RX-28	Butalbital-containing medication	54569034102	
RX-28	Butalbital-containing medication	54569034103	
RX-28	Butalbital-containing medication	54569034104	
RX-28	Butalbital-containing medication	54569034105	
RX-28	Butalbital-containing medication	54569034114	
RX-28	Butalbital-containing medication	54569038800	
RX-28	Butalbital-containing medication	54569039800	
RX-28	Butalbital-containing medication	54569039801	
RX-28	Butalbital-containing medication	54569165500	
RX-28	Butalbital-containing medication	54569165501	
RX-28	Butalbital-containing medication	54569240200	
RX-28	Butalbital-containing medication	54569253800	
RX-28	Butalbital-containing medication	54569253801	
RX-28	Butalbital-containing medication	54569253802	
RX-28	Butalbital-containing medication	54569253803	
RX-28	Butalbital-containing medication	54569253804	
RX-28	Butalbital-containing medication	54569253805	
RX-28	Butalbital-containing medication	54569315800	
RX-28	Butalbital-containing medication	54569344100	
RX-28	Butalbital-containing medication	54569344101	
RX-28	Butalbital-containing medication	54569346200	
RX-28	Butalbital-containing medication	54569346201	
RX-28	Butalbital-containing medication	54569493500	
RX-28	Butalbital-containing medication	54569493501	
RX-28	Butalbital-containing medication	54569502100	
RX-28	Butalbital-containing medication	54569703800	
RX-28	Butalbital-containing medication	54696051301	
RX-28	Butalbital-containing medication	54868053000	
RX-28	Butalbital-containing medication	54868053001	
RX-28	Butalbital-containing medication	54868053002	
RX-28	Butalbital-containing medication	54868053003	
RX-28	Butalbital-containing medication	54868053004	
RX-28	Butalbital-containing medication	54868103100	
RX-28	Butalbital-containing medication	54868103102	
RX-28	Butalbital-containing medication	54868103600	
RX-28	Butalbital-containing medication	54868103601	
RX-28	Butalbital-containing medication	54868103602	
RX-28	Butalbital-containing medication	54868103603	
RX-28	Butalbital-containing medication	54868103604	
RX-28	Butalbital-containing medication	54868103605	

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable

RX-28Butalbital-containing medication54868103606RX-28Butalbital-containing medication54868103700	
RX-28 Butalbital-containing medication 54868103700	
RX-28 Butalbital-containing medication 54868103701	
RX-28 Butalbital-containing medication 54868103703	
RX-28 Butalbital-containing medication 54868103704	
RX-28 Butalbital-containing medication 54868103705	
RX-28 Butalbital-containing medication 54868103706	
RX-28 Butalbital-containing medication 54868105300	
RX-28 Butalbital-containing medication 54868105301	
RX-28 Butalbital-containing medication 54868105302	
RX-28 Butalbital-containing medication 54868105303	
RX-28 Butalbital-containing medication 54868105304	
RX-28 Butalbital-containing medication 54868105305	
RX-28 Butalbital-containing medication 54868107500	
RX-28 Butalbital-containing medication 54868107501	
RX-28 Butalbital-containing medication 54868107502	
RX-28 Butalbital-containing medication 54868107503	
RX-28 Butalbital-containing medication 54868110900	
RX-28 Butalbital-containing medication 54868277800	
RX-28 Butalbital-containing medication 54868277801	
RX-28 Butalbital-containing medication 54868277802	
RX-28 Butalbital-containing medication 54868277803	
RX-28 Butalbital-containing medication 54868331700	
RX-28 Butalbital-containing medication 54868516200	
RX-28 Butalbital-containing medication 54868516201	
RX-28 Butalbital-containing medication 54868516202	
RX-28 Butalbital-containing medication 54868576600	
RX-28 Butalbital-containing medication 54868594300	
RX-28 Butalbital-containing medication 54977012320	
RX-28 Butalbital-containing medication 54977012399	
RX-28 Butalbital-containing medication 55045120800	
RX-28 Butalbital-containing medication 55045120802	
RX-28 Butalbital-containing medication 55045120803	
RX-28 Butalbital-containing medication 55045120806	
RX-28 Butalbital-containing medication 55045120807	
RX-28 Butalbital-containing medication 55045120808	
RX-28 Butalbital-containing medication 55045120809	
RX-28 Butalbital-containing medication 55045158200	
RX-28 Butalbital-containing medication 55045158201	
RX-28 Butalbital-containing medication 55045158202	
RX-28 Butalbital-containing medication 55045158203	
RX-28 Butalbital-containing medication 55045158204	
RX-28 Butalbital-containing medication 55045158205	
RX-28 Butalbital-containing medication 55045158207	
RX-28 Butalbital-containing medication 55045158208	
RX-28 Butalbital-containing medication 55045158209	
RX-28 Butalbital-containing medication 55045235208	
RX-28 Butalbital-containing medication 55045312901	
RX-28 Butalbital-containing medication 55053042501	
RX-28 Butalbital-containing medication 55053042505	
RX-28 Butalbital-containing medication 55081023000	
RX-28 Butalbital-containing medication 55081023001	
RX-28 Butalbital-containing medication 55081023003	
RX-28 Butalbital-containing medication 55081042500	
RX-28 Butalbital-containing medication 55081095400	
RX-28 Butalbital-containing medication 55081095401	
RX-28 Butalbital-containing medication 55081095403	
RX-28 Butalbital-containing medication 55081096100	

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable

			NQF #ACP-042-10
RX-28	Butalbital-containing medication	55081512000	
RX-28	Butalbital-containing medication	55084011515	
RX-28	Butalbital-containing medication	55084011530	
RX-28	Butalbital-containing medication	55084018730	
RX-28	Butalbital-containing medication	55153107301	
RX-28	Butalbital-containing medication	55175009202	
RX-28	Butalbital-containing medication	55175009208	
RX-28	Butalbital-containing medication	55175023400	
RX-28	Butalbital-containing medication	55175198708	
RX-28	Butalbital-containing medication	55175210402	
RX-28	Butalbital-containing medication	55175210501	
RX-28	Butalbital-containing medication	55175210502	
RX-28	Butalbital-containing medication	55175210503	
RX-28	Butalbital-containing medication	55175210600	
RX-28	Butalbital-containing medication	55175210601	
RX-28	Butalbital-containing medication	55175210602	
RX-28	Butalbital-containing medication	55175210603	
RX-28	Butalbital-containing medication	55175210604	
RX-28	Butalbital-containing medication	55175230905	
RX-28	Butalbital-containing medication	55175305602	
RX-28	Butalbital-containing medication	55289002620	
RX-28	Butalbital-containing medication	55289004015	
RX-28	Butalbital-containing medication	55289004020	
RX-28	Butalbital-containing medication	55289004030	
RX-28	Butalbital-containing medication	55289012715	
RX-28	Butalbital-containing medication	55289012725	
RX-28	Butalbital-containing medication	55289020030	
RX-28	Butalbital-containing medication	55289026412	
RX-28	Butalbital-containing medication	55289043912	
RX-28	Butalbital-containing medication	55289069012	
RX-28	Butalbital-containing medication	55289077818	
RX-28	Butalbital-containing medication	55289087910	
RX-28	Butalbital-containing medication	55289087915	
RX-28	Butalbital-containing medication	55289087920	
RX-28	Butalbital-containing medication	55289087930	
RX-28	Butalbital-containing medication	55289097420	
RX-28	Butalbital-containing medication	55726030001	
RX-28	Butalbital-containing medication	55829081510	
RX-28	Butalbital-containing medication	55887035520	
RX-28	Butalbital-containing medication	55887035530	
RX-28	Butalbital-containing medication	55887035540	
RX-28	Butalbital-containing medication	55887056620	
RX-28	Butalbital-containing medication	55887056630	
RX-28	Butalbital-containing medication	55887056660	
RX-28	Butalbital-containing medication	55887091860	
RX-28	Butalbital-containing medication	55887091890	
RX-28	Butalbital-containing medication	55887098805	
RX-28	Butalbital-containing medication	55887098806	
RX-28	Butalbital-containing medication	55887098820	
RX-28		55887098830	
RX-28	Butalbital-containing medication	55887098840	
RX-28	Butalbital-containing medication	55887098882	
RX-28	Butalbital-containing medication	55887098890	
RX-28	Butalbital-containing medication	55947011212	
RX-28	Butalbital-containing medication	55947011220	
RX-28	Butalbital-containing medication	55953063340	
RX-28	Butalbital-containing medication	57362046711	
RX-28	Butalbital-containing medication	57362046713	
			I

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable

			NQF #ACP-042-10
RX-28	Butalbital-containing medication	57362046719	
RX-28	Butalbital-containing medication	57362046784	
RX-28	Butalbital-containing medication	57362062711	
RX-28	Butalbital-containing medication	57424010232	
RX-28	Butalbital-containing medication	57424010332	
RX-28	Butalbital-containing medication	57424010432	
RX-28	Butalbital-containing medication	57779010304	
RX-28	Butalbital-containing medication	57779011104	
RX-28	Butalbital-containing medication	57779011106	
RX-28	Butalbital-containing medication	57866393801	
RX-28	Butalbital-containing medication	57866393802	
RX-28	Butalbital-containing medication	57866393803	
RX-28	Butalbital-containing medication	57866393901	
RX-28	Butalbital-containing medication	57866393902	
RX-28	Butalbital-containing medication	57866393903	
RX-28	Butalbital-containing medication	57866485602	
RX-28	Butalbital-containing medication	57866485603	
RX-28	Butalbital-containing medication	57866485604	
RX-28	Butalbital-containing medication	57866485605	
RX-28	Butalbital-containing medication	57866485606	
RX-28	Butalbital-containing medication	57866485701	
RX-28	Butalbital-containing medication	57866485702	
RX-28	Butalbital-containing medication	57866485703	
RX-28	Butalbital-containing medication	57866485704	
RX-28	Butalbital-containing medication	58016000200	
RX-28	Butalbital-containing medication	58016000230	
RX-28	Butalbital-containing medication	58016000260	
RX-28	Butalbital-containing medication	58016000290	
RX-28	Butalbital-containing medication	58016008900	
RX-28	Butalbital-containing medication	58016008930	
RX-28	Butalbital-containing medication	58016008960	
RX-28	Butalbital-containing medication	58016008990	
RX-28	Butalbital-containing medication	58016009100	
RX-28	Butalbital-containing medication	58016009130	
RX-28	Butalbital-containing medication	58016009160	
RX-28	Butalbital-containing medication	58016009190	
RX-28	Butalbital-containing medication	58016009200	
RX-28	Butalbital-containing medication	58016009230	
RX-28	Butalbital-containing medication	58016009260	
RX-28	Butalbital-containing medication	58016009290	
RX-28	Butalbital-containing medication	58016009300	
RX-28	Butalbital-containing medication	58016009330	
RX-28	Butalbital-containing medication	58016009360	
RX-28	Butalbital-containing medication	58016009390	
RX-28	Butalbital-containing medication	58016023300	
RX-28	Butalbital-containing medication	58016023302	
RX-28	Butalbital-containing medication	58016023310	
RX-28	Butalbital-containing medication	58016023312	
RX-28	Butalbital-containing medication	58016023314	
RX-28	Butalbital-containing medication	58016023315 58016023220	
RX-28	Butalbital-containing medication	58016023320 58016023221	
RX-28	Butalbital-containing medication	58016023321	
RX-28	Butalbital-containing medication	58016023324	
RX-28	Butalbital-containing medication	58016023325	
RX-28	Butalbital-containing medication Butalbital-containing medication	58016023328	
RX-28 RX-28	Butalbital-containing medication Butalbital-containing medication	58016023330 58016023340	
RX-20 RX-28	Butalbital-containing medication	58016023350	
11/1-20	bataibitai-containing methodilon	30010023330	

			NQF #ACP-042-10
RX-28	Butalbital-containing medication	58016023360	
RX-28	Butalbital-containing medication	58016099500	
RX-28	Butalbital-containing medication	58016099510	
RX-28	Butalbital-containing medication	58016099512	
RX-28	Butalbital-containing medication	58016099514	
RX-28	Butalbital-containing medication	58016099515	
RX-28	Butalbital-containing medication	58016099520	
RX-28	Butalbital-containing medication	58016099521	
RX-28	Butalbital-containing medication	58016099524	
RX-28	Butalbital-containing medication	58016099528	
RX-28	Butalbital-containing medication	58016099530	
RX-28	Butalbital-containing medication	58016099540	
RX-28	Butalbital-containing medication	58016099545	
RX-28	Butalbital-containing medication	58016099550	
RX-28	Butalbital-containing medication	58016099560	
RX-28	Butalbital-containing medication	58016099575	
RX-28	Butalbital-containing medication	58436070301	
RX-28	Butalbital-containing medication	58469039333	
RX-28	Butalbital-containing medication	58469048563	
RX-28	Butalbital-containing medication	58469393330	
RX-28	Butalbital-containing medication	58469485630	
RX-28	Butalbital-containing medication	58605050101	
RX-28	Butalbital-containing medication	58605051101	
RX-28	Butalbital-containing medication	58605052401	
RX-28	Butalbital-containing medication	58864085730	
RX-28	Butalbital-containing medication	59010024001	
RX-28	Butalbital-containing medication	59441015301	
RX-28	Butalbital-containing medication	59630017010	
RX-28	Butalbital-containing medication	59702065001	
RX-28	Butalbital-containing medication	59723002501	
RX-28 RX-28	Butalbital-containing medication	59723002502	
RX-28	Butalbital-containing medication Butalbital-containing medication	59743000401 60346061910	
RX-28	Butalbital-containing medication	60346061920	
RX-28	Butalbital-containing medication	60346061928	
RX-28	Butalbital-containing medication	60346061930	
RX-28	Butalbital-containing medication	60346061940	
RX-28	Butalbital-containing medication	60346061990	
RX-28	Butalbital-containing medication	60346070306	
RX-28	Butalbital-containing medication	60346070312	
RX-28	Butalbital-containing medication	60346070315	
RX-28	Butalbital-containing medication	60346070320	
RX-28	Butalbital-containing medication	60346070330	
RX-28	Butalbital-containing medication	60346070350	
RX-28	Butalbital-containing medication	60346072615	
RX-28	Butalbital-containing medication	60346073815	
RX-28	Butalbital-containing medication	60346073820	
RX-28	Butalbital-containing medication	60346091520	
RX-28	Butalbital-containing medication	60346091530	
RX-28		60346095720	
RX-28	Butalbital-containing medication	60951067570	
RX-28	Butalbital-containing medication	60951067585	
RX-28	Butalbital-containing medication	61808011001	
RX-28	Butalbital-containing medication	61808011005	
RX-28	Butalbital-containing medication	62022007001	
RX-28	Butalbital-containing medication	62022007301	
RX-28	Butalbital-containing medication	63629177403	
RX-28	Butalbital-containing medication	63629177405	
L			

			NQF #ACP-042-10
RX-28	Butalbital-containing medication	63629295101	
RX-28	Butalbital-containing medication	63629295102	
RX-28	Butalbital-containing medication	63629295103	
RX-28	Butalbital-containing medication	63629295201	
RX-28	Butalbital-containing medication	63629295202	
RX-28	Butalbital-containing medication	63629295203	
RX-28	Butalbital-containing medication	63629315201	
RX-28	Butalbital-containing medication	63874021925	
RX-28	Butalbital-containing medication	63874021930	
RX-28	Butalbital-containing medication	63874026801	
RX-28	Butalbital-containing medication	63874026802	
RX-28	Butalbital-containing medication	63874026810	
RX-28	Butalbital-containing medication	63874026812	
RX-28	Butalbital-containing medication	63874026814	
RX-28	Butalbital-containing medication	63874026815	
RX-28	Butalbital-containing medication	63874026820	
RX-28	Butalbital-containing medication	63874026821	
RX-28	Butalbital-containing medication	63874026824	
RX-28	Butalbital-containing medication	63874026825	
RX-28	Butalbital-containing medication	63874026828	
RX-28	Butalbital-containing medication	63874026830	
RX-28	Butalbital-containing medication	63874026840	
RX-28	Butalbital-containing medication	63874026850	
RX-28	Butalbital-containing medication	63874026860	
RX-28	Butalbital-containing medication	63874044801	
RX-28	Butalbital-containing medication	63874044802	
RX-28	Butalbital-containing medication	63874044803	
RX-28	Butalbital-containing medication	63874044810	
RX-28	Butalbital-containing medication	63874044820	
RX-28	Butalbital-containing medication	63874044830	
RX-28	Butalbital-containing medication	63874044850	
RX-28	Butalbital-containing medication	63874044860	
RX-28	Butalbital-containing medication	63874044890	
RX-28	Butalbital-containing medication	64980015401	
RX-28	Butalbital-containing medication	64980015405	
RX-28	Butalbital-containing medication	64980015501	
RX-28	Butalbital-containing medication	64980015505	
RX-28	Butalbital-containing medication	65162045910	
RX-28	Butalbital-containing medication	65162045950	
RX-28	Butalbital-containing medication	65234005010	
RX-28	Butalbital-containing medication	65234005050	
RX-28 RX-28	Butalbital-containing medication Butalbital-containing medication	65234005610 65234005650	
RX-20	Butalbital-containing medication	65234006110	
RX-28	Butalbital-containing medication	65893010050	
RX-20	Butalbital-containing medication	66116064830	
RX-20 RX-28	Butalbital-containing medication	66267003815	
RX-28	Butalbital-containing medication	66267003930	
RX-20	Butalbital-containing medication	66267003960	
RX-28	Butalbital-containing medication	66336031430	
RX-28	Butalbital-containing medication	66336061930	
RX-28	Butalbital-containing medication	66336070330	
RX-28	Butalbital-containing medication	66336070360	
RX-28	Butalbital-containing medication	66336070394	
RX-28	Butalbital-containing medication	66813007316	
RX-28	Butalbital-containing medication	66813007401	
RX-28	Butalbital-containing medication	67544001130	
RX-28	Butalbital-containing medication	67544001153	
L	5		

		NQF #ACF	P-042-10
RX-28	Butalbital-containing medication	67544012030	
RX-28	Butalbital-containing medication	67544012053	
RX-28	Butalbital-containing medication	67544012060	
RX-28	Butalbital-containing medication	67544012070	
RX-28	Butalbital-containing medication	67544013930	
RX-28	Butalbital-containing medication	67544013953	
RX-28	Butalbital-containing medication	67544013960	
RX-28	Butalbital-containing medication	67544013970	
RX-28	Butalbital-containing medication	67544034330	
RX-28	Butalbital-containing medication	67544034353	
RX-28	Butalbital-containing medication	67544034360	
RX-28	Butalbital-containing medication	67544034370	
RX-28	Butalbital-containing medication	67544038330	
RX-28	Butalbital-containing medication	67544038353	
RX-28	Butalbital-containing medication	67544038360 67544038370	
RX-28	Butalbital-containing medication	67544038370 67544030430	
RX-28 RX-28	Butalbital-containing medication Butalbital-containing medication	67544039430 67544039453	
RX-28	Butalbital-containing medication	67544039460	
RX-28	Butalbital-containing medication	67544039470	
RX-20	Butalbital-containing medication	67544104530	
RX-28	Butalbital-containing medication	67870011101	
RX-28	Butalbital-containing medication	67870011105	
RX-28	Butalbital-containing medication	68084011400	
RX-28	Butalbital-containing medication	68084011405	
RX-28	Butalbital-containing medication	68084039601	
RX-28	Butalbital-containing medication	68084039611	
RX-28	Butalbital-containing medication	68115005406	
RX-28	Butalbital-containing medication	68115005412	
RX-28	Butalbital-containing medication	68115005430	
RX-28	Butalbital-containing medication	68115005440	
RX-28	Butalbital-containing medication	68115005450	
RX-28	Butalbital-containing medication	68115005460	
RX-28	Butalbital-containing medication	68115005512	
RX-28	Butalbital-containing medication	68115005530	
RX-28	Butalbital-containing medication	68115005630	
RX-28	Butalbital-containing medication	68115005700	
RX-28	Butalbital-containing medication	68115005715	
RX-28	Butalbital-containing medication	68115049948	
RX-28	Butalbital-containing medication	68115062700	
RX-28	Butalbital-containing medication	68387052012 68287052000	
RX-28 RX-28	Butalbital-containing medication	68387052020 68387052030	
RX-28 RX-28	Butalbital-containing medication Butalbital-containing medication	68387052030 68387052060	
RX-20	Butalbital-containing medication	68387052090	
RX-28	Butalbital-containing medication	68453007410	
RX-28	Butalbital-containing medication	68453017010	
101 20	Satalortal containing moded ton		
cd. set	RX code set description ndc		
RX-29	Butorphanol Tartrate (nasal only)	00054309036	
RX-29	Butorphanol Tartrate (nasal only)	00087565041	
RX-29	Butorphanol Tartrate (nasal only)	00378963943	
RX-29	Butorphanol Tartrate (nasal only)	00403479118	
RX-29	Butorphanol Tartrate (nasal only)	54569368100	
RX-29	Butorphanol Tartrate (nasal only)	54569598800	
RX-29	Butorphanol Tartrate (nasal only)	54868320900	
RX-29	Butorphanol Tartrate (nasal only)	54868458300	
RX-29	Butorphanol Tartrate (nasal only)	55175441601	

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable

				NQF #ACF	P-042-10
RX-29	Butorphanol Tartrate (nasal only)	580164	83301		
RX-29	Butorphanol Tartrate (nasal only)	597230	10201		
RX-29	Butorphanol Tartrate (nasal only)	5 99 115			
RX-29	Butorphanol Tartrate (nasal only)	605050	81301		
cd. set	t RX code set description ndc				
RX-42	Dihydroergotamine Mesylate (nasal only	()	00078024598		
RX-42	Dihydroergotamine Mesylate (nasal only		00187024502		
RX-42	Dihydroergotamine Mesylate (nasal only	Ď	00187024503		
RX-42	Dihydroergotamine Mesylate (nasal only	()	00187024504		
RX-42	Dihydroergotamine Mesylate (nasal only	()	66490024598		
cd. set	t RX code set description ndc				
RX-76	Midrin-type medication 00086012005				
RX-76	Midrin-type medication 00086012010				
RX-76	Midrin-type medication 00086012025				
RX-76	Midrin-type medication 00182123401				
RX-76	Midrin-type medication 00247014500				
RX-76	Midrin-type medication 00247014510				
RX-76	Midrin-type medication 00247014515				
RX-76	Midrin-type medication 00247014520				
RX-76	Midrin-type medication 00247014525				
RX-76	Midrin-type medication 00247014550				
RX-76 RX-76	Midrin-type medication 00254427028				
RX-76	Midrin-type medication 00254427033 Midrin-type medication 00304165301				
RX-76	Midrin-type medication 00349878301				
RX-76	Midrin-type medication 00349878305				
RX-76	Midrin-type medication 00349891401				
RX-76	Midrin-type medication 00364234201				
RX-76	Midrin-type medication 00392051268				
RX-76	Midrin-type medication 00403134701				
RX-76	Midrin-type medication 00403134718				
RX-76	Midrin-type medication 00405403901				
RX-76	Midrin-type medication 00440781010				
RX-76	Midrin-type medication 00440781028				
RX-76	Midrin-type medication 00440781060				
RX-76	Midrin-type medication 00516042401				
RX-76 RX-76	Midrin-type medication 00516042405 Midrin-type medication 00516042425				
RX-76	Midrin-type medication 00516042425 Midrin-type medication 00536393201				
RX-76	Midrin-type medication 00536393201				
RX-76	Midrin-type medication 00555036402				
RX-76	Midrin-type medication 00603466421				
RX-76	Midrin-type medication 00603466424				
RX-76	Midrin-type medication 00677112501				
RX-76	Midrin-type medication 00677112503				
RX-76	Midrin-type medication 00677173901				
RX-76					
RX-76	Midrin-type medication 00677194901				
RX-76	Midrin-type medication 00719146810				
RX-76	Midrin-type medication 00781232601				
RX-76	Midrin-type medication 00814486014				
RX-76 RX-76	Midrin-type medication 00839714804 Midrin-type medication 00839756104				
RX-76 RX-76	Midrin-type medication 00839756104 Midrin-type medication 00839756106				
RX-76	Midrin-type medication 00839756109				
RX-76	Midrin-type medication 00879067901				
1					

		NQF #ACP-	-042-10
RX-76	Midrin-type medication 00904158860		
RX-76	Midrin-type medication 00904158870		
RX-76	Midrin-type medication 00904549160		
RX-76	Midrin-type medication 00904549170		
RX-76	Midrin-type medication 00904762260		
RX-76	Midrin-type medication 00904762270		
RX-76	Midrin-type medication 14508030408		
RX-76	Midrin-type medication 17236022901		
RX-76	Midrin-type medication 18837026330		
RX-76	Midrin-type medication 21695027500		
RX-76	Midrin-type medication 21695027530		
RX-76	Midrin-type medication 23490576501		
RX-76	Midrin-type medication 23490576503		
RX-76	Midrin-type medication 35356044704		
RX-76	Midrin-type medication 35356044730		
RX-76	Midrin-type medication 35356044760		
RX-76	Midrin-type medication 35356044790		
RX-76	Midrin-type medication 46672025310		
RX-76	Midrin-type medication 46672025325		
RX-76	Midrin-type medication 47202266901		
RX-76	Midrin-type medication 49326022790		
RX-76	Midrin-type medication 49326032710		
RX-76	Midrin-type medication 49326032750		
RX-76	Midrin-type medication 49727029402		
RX-76	Midrin-type medication 49884081201		
RX-76	Midrin-type medication 49884081204		
RX-76	Midrin-type medication 49999080230		
RX-76	Midrin-type medication 50564050801		
RX-76	Midrin-type medication 50564050805		
RX-76	Midrin-type medication 51081042405		
RX-76	Midrin-type medication 51081042410		
RX-76	Midrin-type medication 51081042425		
RX-76	Midrin-type medication 51285036402		
RX-76	Midrin-type medication 51285036404		
RX-76	Midrin-type medication 51655045129		
RX-76	Midrin-type medication 51655045153		
RX-76	Midrin-type medication 51991039501		
RX-76	Midrin-type medication 51991039502		
RX-76	Midrin-type medication 51991039505		
RX-76 RX-76	Midrin-type medication 52152003902		
RX-76	Midrin-type medication 52152003903		
RX-76	Midrin-type medication 52152003904 Midrin-type medication 52152003905		
RX-76	Midrin-type medication 52152003903 Midrin-type medication 52446057321		
RX-76	Midrin-type medication 52446057324		
RX-76	Midrin-type medication 52949007324 Midrin-type medication 52959044700		
RX-76	Midrin-type medication 52959044700 Midrin-type medication 52959044720		
RX-76	Midrin-type medication 52959044720 Midrin-type medication 52959044730		
RX-76	Midrin-type medication 52959044750		
RX-76	Midrin-type medication 52757044760		
RX-76	Midrin-type medication 52757044700 Midrin-type medication 53002054520		
RX-76	Midrin-type medication 53002054530		
RX-76	Midrin-type medication 53002054550		
RX-76	Midrin-type medication 53159042401		
RX-76	Midrin-type medication 53159042405		
RX-76	Midrin-type medication 53159042425		
RX-76	Midrin-type medication 53506015620		
RX-76	Midrin-type medication 53746014101		

		NQF #ACP-0	042-10
RX-76	Midrin-type medication 53746014102		
RX-76	Midrin-type medication 53746014105		
RX-76	Midrin-type medication 53746014150		
RX-76	Midrin-type medication 54124050924		
RX-76	Midrin-type medication 54124050950		
RX-76	Midrin-type medication 54274079910		
RX-76	Midrin-type medication 54274093810		
RX-76	Midrin-type medication 54569034300		
RX-76	Midrin-type medication 54569034301		
RX-76	Midrin-type medication 54569034302		
RX-76	Midrin-type medication 54569034303		
RX-76	Midrin-type medication 54569034304		
RX-76	Midrin-type medication 54569034317		
RX-76	Midrin-type medication 54569034327		
RX-76	Midrin-type medication 54569287500		
RX-76	Midrin-type medication 54569364300		
RX-76	Midrin-type medication 54569364301		
RX-76	Midrin-type medication 54569466500		
RX-76	Midrin-type medication 54569466501		
RX-76	Midrin-type medication 54569700600		
RX-76	Midrin-type medication 54569714200		
RX-76	Midrin-type medication 54569715200		
RX-76	Midrin-type medication 54868143500		
RX-76	Midrin-type medication 54868143501		
RX-76	Midrin-type medication 54868143502		
RX-76	Midrin-type medication 54868143503		
RX-76	Midrin-type medication 54868151400		
RX-76	Midrin-type medication 54868151401		
RX-76	Midrin-type medication 54868151403		
RX-76	Midrin-type medication 54868151404		
RX-76	Midrin-type medication 54868151405		
RX-76	Midrin-type medication 54868151406		
RX-76	Midrin-type medication 54979014401		
RX-76	Midrin-type medication 54979014405		
RX-76	Midrin-type medication 55045288802		
RX-76	Midrin-type medication 55045288805		
RX-76	Midrin-type medication 55045288806		
RX-76	Midrin-type medication 55045288808		
RX-76	Midrin-type medication 55045288809		
RX-76	Midrin-type medication 55053042001		
RX-76	Midrin-type medication 55053051201		
RX-76	Midrin-type medication 55081034900		
RX-76	Midrin-type medication 55081034901		
RX-76	Midrin-type medication 55081078700		
RX-76	Midrin-type medication 55081078701		
RX-76	Midrin-type medication 55084012320		
RX-76	Midrin-type medication 55153108601 Midrin-type medication 55175210803		
RX-76	Midrin-type medication 55175210803 Midrin-type medication 55289035517		
RX-76	Midrin-type medication 55289035517 Midrin-type medication 55289035520		
RX-76 RX-76	Midrin-type medication 55289035520 Midrin-type medication 55289038317		
RX-76	Midrin-type medication 55289038317 Midrin-type medication 55289038320		
RX-76	Midrin-type medication 55269036320 Midrin-type medication 55289038360		
RX-76	Midrin-type medication 55289038390		
RX-76	Midrin-type medication 55289084230		
RX-76	Midrin-type medication 55269064250 Midrin-type medication 55887026520		
RX-76	Midrin-type medication 55887026520		
RX-76	Midrin-type medication 55887026590		
1070	main type medication 0000/020070		

		NQF #ACP-042-	-10
RX-76	Midrin-type medication 55887077630		
RX-76	Midrin-type medication 55887077660		
RX-76	Midrin-type medication 55887077690		
RX-76	Midrin-type medication 57362060711		
RX-76	Midrin-type medication 57664017908		
RX-76	Midrin-type medication 57664017910		
RX-76	Midrin-type medication 57866020001		
RX-76	Midrin-type medication 57866020801		
RX-76	Midrin-type medication 57866304702		
RX-76	Midrin-type medication 57866304703		
RX-76	Midrin-type medication 57866304704		
RX-76	Midrin-type medication 57866304705		
RX-76	Midrin-type medication 58016028800		
RX-76	Midrin-type medication 58016028812		
RX-76	Midrin-type medication 58016028814		
RX-76	Midrin-type medication 58016028815		
RX-76	Midrin-type medication 58016028818		
RX-76	Midrin-type medication 58016028820		
RX-76	Midrin-type medication 58016028821		
RX-76	Midrin-type medication 58016028824		
RX-76	Midrin-type medication 58016028825		
RX-76	Midrin-type medication 58016028828		
RX-76	Midrin-type medication 58016028830		
RX-76	Midrin-type medication 58016028840		
RX-76	Midrin-type medication 58016028850		
RX-76	Midrin-type medication 58016028860		
RX-76	Midrin-type medication 58016028890		
RX-76	Midrin-type medication 59075057610		
RX-76	Midrin-type medication 59618046015		
RX-76	Midrin-type medication 59879010601		
RX-76	Midrin-type medication 60346062508		
RX-76	Midrin-type medication 60346062510		
RX-76	Midrin-type medication 60346062520		
RX-76	Midrin-type medication 60346062530		
RX-76	Midrin-type medication 60346062560		
RX-76	Midrin-type medication 62584013900		
RX-76	Midrin-type medication 62584013901		
RX-76	Midrin-type medication 62584013911		
RX-76	Midrin-type medication 62584013918		
RX-76	Midrin-type medication 63874050401		
RX-76	Midrin-type medication 63874050404		
RX-76 RX-76	Midrin-type medication 63874050420		
RX-76	Midrin-type medication 63874050428		
RX-76	Midrin-type medication 63874050430		
RX-76 RX-76	Midrin-type medication 63874050440		
RX-76	Midrin-type medication 63874050460		
RX-76	Midrin-type medication 63874050475 Midrin-type medication 63874050490		
RX-76	Midrin-type medication 63874050490 Midrin-type medication 64125010101		
RX-76	Midrin-type medication 64125010101 Midrin-type medication 64125010102		
RX-76	Midrin-type medication 64248012005		
RX-76	Midrin-type medication 64248012005		
RX-76	Midrin-type medication 65162014110		
RX-76	Midrin-type medication 66116047630		
RX-76	Midrin-type medication 66267035410		
RX-76	Midrin-type medication 66267035470		
RX-76	Midrin-type medication 66267035420		
RX-76	Midrin-type medication 66336062520		
1010	main type medication 0000002020		
		NQF #ACP-0	
---	----------------------	------------	
RX-76 Midrin-type med	lication 66336062530		
	lication 66336062590		
	lication 66993060102		
	lication 66993060125		
	lication 68115024230		
	lication 68115024240		
	lication 68115024260		
	lication 68308083010		
xx-70 mildrin-type met			
cd. set RX code set desc	ription ndc		
RX-121 Triptan (nasal o			
X-121 Triptan (nasal o	57		
X-121 Triptan (nasal o			
X-121 Triptan (nasal o			
X-121 Triptan (nasal o	nly) 58016123101		
X-121 Triptan (nasal o	nly) 63874089706		
RX-121 Triptan (nasal o	nly) 68115072506		
cd. set RX code set desc	ription pdc		
RX-122 Triptan (oral on	•		
RX-122 Triptan (oral on			
RX-122 Triptan (oral on			
X-122 Triptan (oral on			
X-122 Triptan (oral on			
X-122 Triptan (oral on			
X-122 Triptan (oral on			
X-122 Triptan (oral on			
X-122 Triptan (oral on	57 ·		
X-122 Triptan (oral on	57 ·		
X-122 Triptan (oral on	57 ·		
X-122 Triptan (oral on			
X-122 Triptan (oral on	57 ·		
X-122 Triptan (oral on	57 ·		
X-122 Triptan (oral on			
X-122 Triptan (oral on			
X-122 Triptan (oral on	lý) 00037720920		
X-122 Triptan (oral on			
X-122 Triptan (oral on X-122 Triptan (oral on			
RX-122 Triptan (oral on			
RX-122 Triptan (oral on			
RX-122 Triptan (oral on			
X-122 Triptan (oral on	ly) 00062208512		

		NQF #ACP-042-	10
RX-122 Triptan (oral only)	00093022219		
RX-122 Triptan (oral only)	00093022290		
RX-122 Triptan (oral only)	00093022390		
RX-122 Triptan (oral only)	00093022490		
RX-122 Triptan (oral only)	00173045003		
RX-122 Triptan (oral only)	00173045900		
RX-122 Triptan (oral only)	00173046002		
RX-122 Triptan (oral only)	00173056100		
RX-122 Triptan (oral only)	00173056200		
RX-122 Triptan (oral only)	00173073500		
RX-122 Triptan (oral only)	00173073601		
RX-122 Triptan (oral only)	00173073602		
RX-122 Triptan (oral only)	00173073701		
RX-122 Triptan (oral only) RX-122 Triptan (oral only)	00173073702 00173075000		
RX-122 Triptan (oral only) RX-122 Triptan (oral only)	00310020920		
RX-122 Triptan (oral only)	00310020920		
RX-122 Triptan (oral only)	00310021020		
RX-122 Triptan (oral only)	00310021321		
RX-122 Triptan (oral only)	00378563059		
RX-122 Triptan (oral only)	00378563159		
RX-122 Triptan (oral only)	00378563259		
RX-122 Triptan (oral only)	12280028909		
RX-122 Triptan (oral only)	16252059099		
RX-122 Triptan (oral only)	16252059199		
RX-122 Triptan (oral only)	16252059299		
RX-122 Triptan (oral only)	16590012709		
RX-122 Triptan (oral only)	16590012809		
RX-122 Triptan (oral only)	16590014409		
RX-122 Triptan (oral only)	16590014509		
RX-122 Triptan (oral only)	16590020112		
RX-122 Triptan (oral only)	21695015409		
RX-122 Triptan (oral only)	21695022209		
RX-122 Triptan (oral only)	21695087112		
RX-122 Triptan (oral only)	21695087209		
RX-122 Triptan (oral only)	21695087309		
RX-122 Triptan (oral only)	21695087409		
RX-122 Triptan (oral only) RX-122 Triptan (oral only)	35356016909 35356025212		
RX-122 Triptan (oral only) RX-122 Triptan (oral only)	35356025212		
RX-122 Triptan (oral only) RX-122 Triptan (oral only)	35356025318		
RX-122 Triptan (oral only)	35356025409		
RX-122 Triptan (oral only)	35356027512		
RX-122 Triptan (oral only)	35356039512		
RX-122 Triptan (oral only)	35356041203		
RX-122 Triptan (oral only)	35356043809		
RX-122 Triptan (oral only)	35356043909		
RX-122 Triptan (oral only)	52959042209		
RX-122 Triptan (oral only)	52959047709		
RX-122 Triptan (oral only)	52959078606		
RX-122 Triptan (oral only)	52959090909		
RX-122 Triptan (oral only)	54569419000		
RX-122 Triptan (oral only)	54569419100		
RX-122 Triptan (oral only)	54569419101		
RX-122 Triptan (oral only)	54569461200		
RX-122 Triptan (oral only)	54569522200		
RX-122 Triptan (oral only)	54569542600		
RX-122 Triptan (oral only)	54569542601		

		NQF #ACP	-042-10
RX-122 Triptan (oral only)	54868008500		
RX-122 Triptan (oral only)	54868008501		
RX-122 Triptan (oral only)	54868377700		
RX-122 Triptan (oral only)	54868385200		
RX-122 Triptan (oral only)	54868408600		
RX-122 Triptan (oral only)	54868421500		
RX-122 Triptan (oral only)	54868425100		
RX-122 Triptan (oral only)	54868425101		
RX-122 Triptan (oral only)	54868425102		
RX-122 Triptan (oral only)	54868425103		
RX-122 Triptan (oral only)	54868449900		
RX-122 Triptan (oral only)	54868449901		
RX-122 Triptan (oral only)	54868511800		
RX-122 Triptan (oral only)	54868552700		
RX-122 Triptan (oral only)	54868552701		
RX-122 Triptan (oral only)	54868552800		
RX-122 Triptan (oral only)	54868559300		
RX-122 Triptan (oral only)	54868597800		
RX-122 Triptan (oral only)	54868602300		
RX-122 Triptan (oral only)	55045225009		
RX-122 Triptan (oral only)	55045304009		
RX-122 Triptan (oral only)	55045373109		
RX-122 Triptan (oral only)	55111073609		
RX-122 Triptan (oral only)	55111073709		
RX-122 Triptan (oral only)	55111073809		
RX-122 Triptan (oral only)	55175405509		
RX-122 Triptan (oral only)	55887018712		
RX-122 Triptan (oral only)	55887018809		
RX-122 Triptan (oral only)	55887021009		
RX-122 Triptan (oral only)	55887044109		
RX-122 Triptan (oral only)	55887051206		
RX-122 Triptan (oral only)	55887051309		
RX-122 Triptan (oral only)	55887051318		
RX-122 Triptan (oral only)	55887051327		
RX-122 Triptan (oral only)	55887051330		
RX-122 Triptan (oral only)	57866018702		
RX-122 Triptan (oral only)	58016024609		
RX-122 Triptan (oral only)	58016083801		
RX-122 Triptan (oral only)	58016093800		
RX-122 Triptan (oral only)	58016093806		
RX-122 Triptan (oral only) RX-122 Triptan (oral only)	58016093830 58016093860		
RX-122 Triptan (oral only) RX-122 Triptan (oral only)	58016093860		
RX-122 Triptan (oral only) RX-122 Triptan (oral only)	58016487701		
RX-122 Triptan (oral only) RX-122 Triptan (oral only)	58016557409		
RX-122 Triptan (oral only) RX-122 Triptan (oral only)	58016571100		
RX-122 Triptan (oral only)	58016571103		
RX-122 Triptan (oral only)	58016571130		
RX-122 Triptan (oral only)	58016571160		
RX-122 Triptan (oral only)	58016571190		
RX-122 Triptan (oral only)	58016571206		
RX-122 Triptan (oral only)	59075074089		
RX-122 Triptan (oral only)	59762185009		
RX-122 Triptan (oral only)	59762185109		
RX-122 Triptan (oral only)	59762185209		
RX-122 Triptan (oral only)	62756052069		
RX-122 Triptan (oral only)	62756052088		
RX-122 Triptan (oral only)	62756052169		
	02.00002107		

	NQF #AG	CP-042-10
RX-122 Triptan (oral only)	62756052188	
RX-122 Triptan (oral only)	62756052269	
RX-122 Triptan (oral only)	62756052288	
RX-122 Triptan (oral only)	63304009719	
RX-122 Triptan (oral only)	63304009819	
RX-122 Triptan (oral only)	63304009919	
RX-122 Triptan (oral only)	63481002509	
RX-122 Triptan (oral only)	63874089809 65862014626	
RX-122 Triptan (oral only) RX-122 Triptan (oral only)	65862014636 65862014736	
RX-122 Triptan (oral only) RX-122 Triptan (oral only)	65862014836	
RX-122 Triptan (oral only)	68071026206	
RX-122 Triptan (oral only)	68084033911	
RX-122 Triptan (oral only)	68084033997	
RX-122 Triptan (oral only)	68084034011	
RX-122 Triptan (oral only)	68084034097	
RX-122 Triptan (oral only)	68084034111	
RX-122 Triptan (oral only)	68084034197	
RX-122 Triptan (oral only)	68115069609	
RX-122 Triptan (oral only)	68115070506	
RX-122 Triptan (oral only)	68115073712	
RX-122 Triptan (oral only)	68115077906	
RX-122 Triptan (oral only)	68115088206 68115000700	
RX-122 Triptan (oral only) RX-122 Triptan (oral only)	68115090709 68258300801	
RX-122 Triptan (oral only)	68258300901	
	00230300701	
cd. set RX code set description	n ndc	
RX-123 Triptan (subcutaneous		
RX-123 Triptan (subcutaneous	only) 00173044902	
RX-123 Triptan (subcutaneous	only) 00173044903	
RX-123 Triptan (subcutaneous		
RX-123 Triptan (subcutaneous RX-123 Triptan (subcutaneous		
RX-123 Triptan (subcutaneous		
RX-123 Triptan (subcutaneous		
RX-123 Triptan (subcutaneous		
RX-123 Triptan (subcutaneous		
RX-123 Triptan (subcutaneous	onlý) 49884048252	
RX-123 Triptan (subcutaneous	only) 49884048299	
RX-123 Triptan (subcutaneous	only) 49884048352	
RX-123 Triptan (subcutaneous		
RX-123 Triptan (subcutaneous RX-123 Triptan (subcutaneous		
RX-123 Triptan (subcutaneous		
RX-123 Triptan (subcutaneous		
RX-123 Triptan (subcutaneous		
RX-123 Triptan (subcutaneous		
RX-123 Triptan (subcutaneous		
RX-123 Triptan (subcutaneous		
L		

NQF #ACF	P-042-10	
RX-123Triptan (subcutaneous only)55045351201RX-123Triptan (subcutaneous only)55390031510RX-123Triptan (subcutaneous only)63323027301RX-123Triptan (subcutaneous only)64679072801RX-123Triptan (subcutaneous only)66860002206RX-123Triptan (subcutaneous only)68115077002cd. set RX code set descriptionndc		
RX-174DihydroergotamineMesylate (injection only)00078004101RX-174DihydroergotamineMesylate (injection only)00078004103RX-174DihydroergotamineMesylate (injection only)00247093001RX-174DihydroergotamineMesylate (injection only)00574085005RX-174DihydroergotamineMesylate (injection only)00574085010RX-174DihydroergotamineMesylate (injection only)54569233000RX-174DihydroergotamineMesylate (injection only)55390001310RX-174DihydroergotamineMesylate (injection only)66490004101		
2a.9 Denominator Exclusions (<i>Brief text description of exclusions from the target population</i>): Does not apply		 Comment [k9]: 11 Risk factors that influence outcomes should not be specified as exclusions. 12 Patient preference is not a clinical
2a.10 Denominator Exclusion Details (<i>All information required to collect exclusions to the denominator, including all codes, logic, and definitions</i>): Does not apply		exception to eligibility and can be influenced by provider interventions.
2a.11 Stratification Details/Variables (All information required to stratify the measure including the stratification variables, all codes, logic, and definitions): Does not apply		
2a.12-13 Risk Adjustment Type: no risk adjustment necessary		
2a.14 Risk Adjustment Methodology/Variables (<i>List risk adjustment variables and describe conceptual models, statistical models, or other aspects of model or method</i>) :		
 2a.15-17 Detailed risk model available Web page URL or attachment: 2a.18-19 Type of Score: rate/proportion 2a.20 Interpretation of Score: better quality = higher score 2a.21 Calculation Algorithm (<i>Describe the calculation of the measure as a flowchart or series of steps</i>): 1. Exclude members who meet denominator exclusion criteria 2. Assign a YES or NO result to remaining members based on numerator response 3. Rate = YES/[YES+NO] 		
2a.22 Describe the method for discriminating performance <i>(e.g., significance testing)</i> : Over 3.600 patients met the denominator from a geographically diverse 15 million member benchmark database. More than 1900 patients did not meet numerator compliance, indicating a significant population with a gap in care. The subsequent compliance rate was 66.0 percent.		
 2a.23 Sampling (Survey) Methodology If measure is based on a sample (or survey), provide instructions for obtaining the sample, conducting the survey and guidance on minimum sample size (response rate): A 15 million patient population sample was chosen to analyze the potential patient safety gap in care. The sample was derived from more than 60 million patients based on criteria including national geographic representation, commercial health coverage and patient age less than 65. 		
2a.24 Data Source (<i>Check the source(s) for which the measure is specified and tested</i>) pharmacy data, Electronic adminstrative data/claims		
2a.25 Data source/data collection instrument (<i>Identify the specific data source/data collection instrument, e.g. name of database, clinical registry, collection instrument, etc.</i>): Our data source is a proprietary Ingenix provider database that includes more than 60 million patients, over		
Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable	41	

multiple years. It includes data from multiple payors. This measure specifically uses the following data from this database: member demographics, ICD-9 codes, revenue codes, CPT codes, and place of service codes. Pharmacy lab data is can be used in this measure but it not required.

2a.26-28 Data source/data collection instrument reference web page URL or attachment:

2a.29-31 Data dictionary/code table web page URL or attachment: Attachment Input Guide_NQF-634007901545951692.doc

2a.32-35 Level of Measurement/Analysis (*Check the level(s) for which the measure is specified and tested*)

Population: states, Population: counties or cities, Program: Disease management, Program: QIO, Multisite/corporate chain, Integrated delivery system, Health Plan, Facility/Agency, Clinicians: Group, Clinicians: Individual, Can be measured at all levels

2a.36-37 Care Settings (*Check the setting(s*) for which the measure is specified and tested) nursing home (NH) /Skilled Nursing Facility (SNF), Rehabilitation Facility, Ambulatory Care: Clinic, Ambulatory Care: Emergency Dept, Ambulatory Care: Hospital Outpatient

2a.38-41 Clinical Services (*Healthcare services being measured, check all that apply*) Clinicians: PA/NP/Advanced Practice Nurse, Clinicians: Physicians (MD/DO)

TESTING/ANALYSIS

2b. Reliability testing

2b.1 Data/sample *(description of data/sample and size)*: Reliability is tested by using multiple databases. There are three primary databases that we use: 1) a customer acceptance (CAT) database that includes approximately 4000 members who satisfy the condition confirmation criteria; 2) a one million member face validity testing (FVT) database that is geographically diverse; and 3) a 15 million member benchmark database that is geographically diverse. All databases represent predominately a commercial population less than 65 year of age.

2b.2 Analytic Method (type of reliability & rationale, method for testing): Quality assurance of each measure is accomplished through the testing using multiple methods and databases. Types of testing, data samples and volume vary to ensure the integrity of the measure. Rigorous development, analysis and testing processes are deployed for creating measure specifications. Software testing ensures the software is working as designed. Reliability and validity testing of measures is based on differing data samples and volume of members. National benchmarks are created on a large volume set of data representing members throughout the United States. All quality checks for all measure results must have consistent results and meet expected outcomes based on industry knowledge and experience.

Customer Acceptance Testing (CAT) is an important quality process. CAT ensures that the clinical measures are functioning as intended and that they generate accurate results for typical billing patterns. Using actual claims data a team of business analysts, nurses, and health services researchers conducts a detailed analysis of the output. For each clinical condition in the product (e.g., Diabetes Mellitus, Coronary Artery Disease, etc.) there is a set of CAT data with at least 4000 members who satisfy the condition confirmation criteria. This data is extracted from a large (50+ million member) multi-payer benchmark database and contains inpatient, outpatient, pharmacy, and laboratory data. The testing team analyzes claims from individual members and compares the creation of denominators (target population), numerators, and exclusions from this manual review process to output results from the quality measure.

Regression testing is the part of CAT that verifies the reliability of the product across software releases. For a new release the testing team confirms that every unchanged measure produces the same results as in previous releases, accounting for systematic changes to the software (e.g., code updates, logic changes, etc). Regression testing is conducted at multiple points throughout the software development cycle.

2b.3 Testing Results (reliability statistics, assessment of adequacy in the context of norms for the test

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable

Comment [KP10]: 2b. Reliability testing demonstrates the measure results are repeatable, producing the same results a high proportion of the time when assessed in the same population in the same time period.

Comment [k11]: 8 Examples of reliability testing include, but are not limited to: interrater/abstractor or intra-rater/abstractor studies; internal consistency for multi-item scales; test-retest for survey items. Reliability testing may address the data items or final measure score.



<i>conducted)</i> : Given the size of our benchmark database, it is the most reliable source for compliance results. Over 4,000 members from the benchmark database met the denominator definition for this measure. The overall compliance rate was 66.0 percent.		
2c. Validity testing		 Comment [KP12]: 2c. Validity testing
2c.1 Data/sample <i>(description of data/sample and size)</i> : Our data sample for face validity testing includes a geographically diverse one million member database. Our data sample for benchmark testing includes a geographically diverse 15 million member database. Both databases represent predominately a commercial population less than 65 year of age.		demonstrates that the measure reflects the quality of care provided, adequately distinguishing good and poor quality. If face validity is the only validity addressed, it is systematically assessed.
 2c.2 Analytic Method (type of validit) & rationale, method for testing): Face Validity Testing (FVT) is the final testing step in the software release cycle. One million members are randomly selected from the large multi-payer benchmark database and their claims data is processed through the software. The Medical Director reviews the results to verify that: Prevalence rates for a condition are comparable to nationally published rates Compliance rates for a measure are comparable to the rates reported in the published literature or by other national sources (e.g. HEDIS). If no comparable sources are available, the rates are judged based on what is clinically reasonable. In addition, all results are reviewed for face validity by members of an external physician clinical consultant panel. A similar review of benchmark test results occurs in conjunction with a software release. With benchmark testing, 15 million members are randomly selected from the large multi-payer benchmark database and their claims data is processed through the software. Our claims-based measures have been validated using a chart review comparison process. This validation project is summarized below: Goal: evaluate the reliability of claims-based measure results using chart review as the gold standard 		 Comment [k13]: 9 Examples of validity testing include, but are not limited to: determining if measure scores adequately distinguish between providers known to have good or poor quality assessed by another valid method; correlation of measure scores with another valid indicator of quality for the specific topic; ability of measure scores to predict scores on some other related valid measure; content validity for multi-item scales/tests. Face validity is a subjective assessment by experts of whether the measure reflects the quality of care (e.g., whether the proportion of patients with BP < 140/90 is a marker of quality. If face validity is the only validity addressed, it is systematically assessed (e.g., ratings by relevant stakeholders) and the measure is judged to represent quality care for the specific topic and that the measure focus is the most important aspect of quality for the specific topic.
Methods: The charts of 100 members from two clinics in one city were reviewed. Results from our claims-based measures were compared to information present in the chart. During this process, 726 measures were evaluated. Results:		Comment [KP14]: 2d. Clinically necessary measure exclusions are identified and must be:
 The overall error rate was less than 5%. The error rate varied depending on the type of claim required for numerator compliance and is summarized as follows: The error rate was highest with medications, with an 11 percent error rate (2/18). From chart review, it was difficult to tell if this represented a real error, a medication sample was provided, or the prescription was never filled). The error rate was 4 percent (14/318) for measures that required labs for numerator compliance. It was noted that a claims-based measure approach sometimes identified labs that were missing in chart review. The error rate for office visit and specialty appointments was 2 percent (8/390). Of note, administrative claims was more likely than chart review to identify relevant office and specialty visits, particularly for appointments that occurred outside the clinic or network. Errors were found related to coding in claims data, not due to the claims-based measures or methodology. These errors were not quantified. 2c.3 Testing Results (statistical results, assessment of adequacy in the context of norms for the test conducted): 	2c C□ P□ M□	 supported by evidence of sufficient frequency of occurrence so that results are distorted without the exclusion; AND a clinically appropriate exception (e.g., contraindication) to eligibility for the measure focus; AND precisely defined and specified: —if there is substantial variability in exclusions across providers, the measure is specified so that exclusions are computable and the effect on the measure is transparent (i.e., impact clearly delineated, such as number of cases excluded, exclusion rates by type of exclusion); if patient preference (e.g., informed decisionmaking) is a basis for exclusion, there must be evidence that it strongly impacts performance on the measure and the information about patient
Summarized in 2b3 2d. Exclusions Justified	M□ N□ 2d C□	preference and the effect on the measure is transparent (e.g., numerator category computed separately, denominator exclusion category computed separately).
2d.1 Summary of Evidence supporting exclusion(s): This measure does not include any exclusions.	P M N	 Comment [k15]: 10 Examples of evidence that an exclusion distorts measure results include, but are not limited to: frequency of occurrence, sensitivity analyses with and
2d.2 Citations for Evidence:		without the exclusion, and variability of exclusions across providers.

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable

2d.3 Data/sample (description of data/sample and size): 2d.4 Analytic Method (type analysis & rationale): 2d.5 Testing Results (e.g., frequency, variability, sensitivity analyses): 2e. Risk Adjustment for Outcomes/ Resource Use Measures[2e.1 Data/sample (description of data/sample and size): This measure does not include risk adjustment. 2e.2 Analytic Method (type of risk adjustment, analysis, & rationala): 2e.3 Testing Results (risk model performance metrics): 2e.4 If outcome or resource use measure is not risk adjusted, provide rationale: 2f. Identification of Meaningful Differences in Performance[2f.1 Data/sample from Testing or Current Use (description of data/sample and size): Our benchmark database represents predominately a commercial population less than 65 year of age. 2f.2 Methods to identify statistically significant and practically/meaningfully differences in performance (type of analysis & rationale): 1. Prevalence rates for a condition are comparable to the rates reported in the published rates 2. Compliance rates for a condition are comparable to the rates reported in the published rates 2. Complance rates for a consult and practically indicant and meaningfully differences in performance, the rational sources (e.g. HEDIS). If no comparable sources are available, the rates are judged based on what is clinically reasonable. 1. addition, all results are systematically reviewed for face validity by members of an external physician clinical consultant panel. 2f. Gompar			
2d.5 Testing Results (e.g., frequency, variability, sensitivity analyses): 2e. Risk Adjustment for Outcomes/ Resource Use Measures[2e.1 Data/sample (description of data/sample and size): This measure does not include risk adjustment. 2e.2 Analytic Method (type of risk adjustment, analysis, & rationald): 2e.3 Testing Results (risk model performance metrics): 2e.4 If outcome or resource use measure is not risk adjusted, provide rationale: 2f. Identification of Meaningful Differences in Performance[2f. Identification of Meaningful Differences in Performance[2f. 1 Data/sample from Testing or Current Use (description of data/sample and size): Our benchmark data sample includes a geographically diverse 15 million member benchmark database. The database represents predominately a commercial population less than 65 year of age. 2f. 2 Methods to identify statistically significant and practically/meaningfully differences in performance (type of analysis & rationale): During benchmark testing, 15 million members are randomly selected from the large multi-payer benchmark database and their claims data is processed through the software. The Medical Director reviews the results to verify that: 1. Prevalence rates for a condition are comparable to nationally published rates 2. Compilance rates for a sensure are comparable to nationally published rates 2. Compilance rates for a sensure are comparable to nationally published rates 2. Compilance rates for a sensure are comparable to nationally published rates	2d.3 Data/sample (description of data/sample and size):		
2e. Risk Adjustment for Outcomes/ Resource Use Measures 2e. 1 Data/sample (description of data/sample and size): This measure does not include risk adjustment. 2e. 2 Analytic Method (type of risk adjustment, analysis, & rationald): 2e. 3 Testing Results (risk model performance metrics): 2e. 4 If outcome or resource use measure is not risk adjusted, provide rationale: 2f. Identification of Meaningful Differences in Performance 2f. I. Identification of ata/sample and size): Our benchmark database represents predominately a commercial population less than 65 year of age. 2f. 2. Methods to identify statistically significant and practically/meaningfully differences in performance (type of analysis & rationale): During benchmark database and their claims data is processed through the software. The Medical Director reviews the results to varify that: 1. Prevalence rates for a condition are comparable to nationally published rates 2. Compliance rates for a measure are comparable to nationally published rates 2. Complance rates for a measure are comparable sources are available, the rates are judged based on what is clinically reasonable. 1. Revalence rates for a condiant published interature or by othe	2d.4 Analytic Method (type analysis & rationale):		
2e. Risk Adjustment for Outcomes/ Resource Use Measures 2e. 1 Data/sample (description of data/sample and size): This measure does not include risk adjustment. 2e. 2 Analytic Method (type of risk adjustment, analysis, & rationald): 2e. 3 Testing Results (risk model performance metrics): 2e. 4 If outcome or resource use measure is not risk adjusted, provide rationale: 2f. Identification of Meaningful Differences in Performance 2f. I. Identification of ata/sample and size): Our benchmark database represents predominately a commercial population less than 65 year of age. 2f. 2. Methods to identify statistically significant and practically/meaningfully differences in performance (type of analysis & rationale): During benchmark database and their claims data is processed through the software. The Medical Director reviews the results to varify that: 1. Prevalence rates for a condition are comparable to nationally published rates 2. Compliance rates for a measure are comparable to nationally published rates 2. Complance rates for a measure are comparable sources are available, the rates are judged based on what is clinically reasonable. 1. Revalence rates for a condiant published interature or by othe			
2e.1 Data/sample (description of data/sample and size): This measure does not include risk adjustment. 2e 2e.2 Analytic Method (type of risk adjustment, analysis, & rationald): 2e 2e.3 Testing Results (risk model performance metrics): P 2e.4 If outcome or resource use measure is not risk adjusted, provide rationale: NA 2f. Identification of Meaningful Differences in Performance NA 2f. Identification of Meaningful Differences (description of data/sample and size): Our benchmark database represents predominately a commercial population member benchmark database. The database represents predominately a commercial population less than 65 year of age. 2f. 2 Methods to Identify statistically significant and practically/meaningfully differences in performance (lype of analysis & rationale): During benchmark testing, 15 million members are randomly selected from the large multi-payer benchmark database and their claims data is processed through the software. The Medical Director reviews the results to verify that: 1. Prevalence rates for a condition are comparable to nationally published rates 2. Compliance rates for a measure are comparable to nationally published rates 2. Compliance rates for a measure are comparable to nationally published rates 2. Compliance rates for a measure are comparable to nationally published rates 2. Compliance rates for a measure are comparable to nationally published rates 2. Compliance rates for a condition are comparable to the rates reported in th	2d.5 Testing Results (e.g., frequency, variability, sensitivity analyses):		
2e.2 Analytic Method (type of risk adjustment, analysis, & rationald): 2e 2e.3 Testing Results (risk model performance metrics): 2e 2e.4 If outcome or resource use measure is not risk adjusted, provide rationale: NA 2f. Identification of Meaningful Differences in Performance] NA 2f. 1 Data/sample from Testing or Current Use (description of data/sample and size): Our benchmark data sample includes a geographically diverse 15 million member benchmark database. The database represents predominately a commercial population less than 65 year of age. 2f. 2 Methods to identify statistically significant and practically/meaningfully differences in performance (type of analysis & rationale): 2f 2 Compliance rates for a condition are comparable to nationally published rates 2. Compliance rates for a condition are comparable to nationally published rates 2. Compliance rates for a condition are comparable to nationally published rates 2f 2. Compliance rates for a condition are comparable to nationally published rates 2f 2. Compliance rates for a condition are comparable ton the rates reported in the published literature or by other national sources (e.g. HEDIS). If no comparable to nationally published rates 2f 2f. 3 Provide Measure Scores from Testing or Current Use (description of scores, e.g., distribution by guartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance); Summarized in 2b3 2g 2g. Comparability of Mult	2e. Risk Adjustment for Outcomes/ Resource Use Measures		[
2e.3 Testing Results (risk model performance metrics): 2e 2e.4 If outcome or resource use measure is not risk adjusted, provide rationale: NA 2f. Identification of Meaningful Differences in Performance NA 2f.1 Identification of Meaningful Differences in Performance NA 2f.1 Identification of Meaningful Differences in Performance NA 2f.1 Data/sample from Testing or Current Use (description of data/sample and size): Our benchmark database represents predominately a commercial population less than 65 year of age. Our benchmark database represents predominately a commercial population less than 65 year of age. 2f.2 Methods to identify statistically significant and practically/meaningfully differences in performance (Type of analysis & rationale): During benchmark testing, 15 million members are randomly selected from the large multi-payer benchmark database and their claims data is processed through the software. The Medical Director reviews the results to verify that: 1. Prevalence rates for a condition are comparable to nationally published rates 2. Compliance rates for a condition are comparable sources are available, the rates are judged based on what is clinically reasonable. In addition, all results are systematically reviewed for face validity by members of an external physician clinical consultant panel. Zf 2f. 3 Provide Measure Scores from Testing or Current Use (description of scores, e.g., distribution by guartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in Performance): Zf <td>2e.1 Data/sample (description of data/sample and size): This measure does not include risk adjustment.</td> <td></td> <td></td>	2e.1 Data/sample (description of data/sample and size): This measure does not include risk adjustment.		
2e.3 Testing Results (risk model performance metrics): C 2e.4 If outcome or resource use measure is not risk adjusted, provide rationale: N 2f. Identification of Meaningful Differences in Performance N 2f. 1 Data/sample from Testing or Current Use (description of data/sample and size): Our benchmark database represents predominately a commercial population less than 65 year of age. N 2f. 2 Methods to identify statistically significant and practically/meaningfully differences in performance (Type of analysis & rationale): During benchmark database and their claims data is processed through the software. The Medical Director reviews the results to verify that: 1. Prevalence rates for a condition are comparable to nationally published rates 2. Compliance rates for a measure are comparable to the rates reported in the published literature or by other national sources (e.g. HEDIS). If no comparable sources are available, the rates are judged based on what is clinically reviewed for face validity by members of an external physician clinical consultant panel. 2f. 3 Provide Measure Scores from Testing or Current Use (description of scores, e.g., distribution by puartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance; in performance; 2g. Comparability of Multiple Data Sources/Methods 2g 2g. 2 Analytic Method (type of analysis & rationale); 2g 2g. 3 Testing Results (e.g., correlation statistics, comparison of rankings); N <td>2e.2 Analytic Method (type of risk adjustment, analysis, & rationale):</td> <td></td> <td></td>	2e.2 Analytic Method (type of risk adjustment, analysis, & rationale):		
2e.4 If outcome or resource use measure is not risk adjusted, provide rationale: NA 2f. Identification of Meaningful Differences in Performance Identification of Meaningful Differences in Performance 2f. 1 Data/sample includes a geographically diverse 15 million member benchmark database. The database represents predominately a commercial population less than 65 year of age. Image: Commercial population less than 65 year of age. 2f. 2 Methods to identify statistically significant and practically/meaningfully differences in performance (<i>type of analysis & rationale</i>): Image: Commercial population less than 65 year of age. 2f. 2 Methods to identify statistically significant and practically/meaningfully differences in performance (<i>type of analysis & rationale</i>): During benchmark testing, 15 million members are randomly selected from the large multi-payer benchmark database and their claims data is processed through the software. The Medical Director reviews the results to verify that: Image: Compliance rates for a condition are comparable to nationally published rates 2. Compliance rates for a condition are comparable to the rates reported in the published literature or by other national sources (e.g. HEDIS). If no comparable sources are available, the rates are judged based on what is clinically panel. 2f 2f. 3 Provide Measure Scores from Testing or Current Use (description of scores, e.g., distribution by purfile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance?: 2g 2g. Comparability of Multiple Data Sources/Methods 2g 2g <	2e.3 Testing Results (risk model performance metrics):	C P M	
2f.1 Data/sample from Testing or Current Use (description of data/sample and size): Our benchmark data sample includes a geographically diverse 15 million member benchmark database. The database represents predominately a commercial population less than 65 year of age. 2f.2 Methods to identify statistically significant and practically/meaningfully differences in performance (type of analysis & rationale): During benchmark database and their claims data is processed through the software. The Medical Director reviews the results to verify that: 1. Prevalence rates for a condition are comparable to nationally published rates 2. Compliance rates for a condition are comparable to the rates reported in the published literature or by other national sources (e.g. HEDIS). If no comparable sources are available, the rates are judged based on what is clinical to easily reviewed for face validity by members of an external physician clinical consultant panel. 2f. 3 Provide Measure Scores from Testing or Current Use (description of scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance): Summarized in 2b3 2g. Comparability of Multiple Data Sources/Methods 2g 2g.1 Data/sample (description of data/sample and size): 2g 2g.3 Testing Results (e.g., correlation statistics, comparison of rankings): NI 2h. Disparities in Care 2h	2e.4 If outcome or resource use measure is not risk adjusted, provide rationale:		
data sample includes a geographically diverse 15 million member benchmark database. The database represents predominately a commercial population less than 65 year of age. 2f.2 Methods to identify statistically significant and practically/meaningfully differences in performance (type of analysis & rationale): During benchmark testing, 15 million members are randomly selected from the large multi-payer benchmark database and their claims data is processed through the software. The Medical Director reviews the results to verify that: 1. Prevalence rates for a condition are comparable to nationally published rates 2. Compliance rates for a condition are comparable to the rates reported in the published literature or by other national sources (e.g. HEDIS). If no comparable sources are available, the rates are judged based on what is clinically reasonable. In addition, all results are systematically reviewed for face validity by members of an external physician clinical consultant panel. 2f. 3 Provide Measure Scores from Testing or Current Use (description of scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance): Summarized in 2b3 2g. Comparability of Multiple Data Sources/Methods 2g 2g.1 Data/sample (description of data/sample and size): 2g 2g.3 Testing Results (e.g., correlation statistics, comparison of rankings): Na 2h. Disparities in Care 2h	2f. Identification of Meaningful Differences in Performance		
(type of analysis & rationale): During benchmark testing, 15 million members are randomly selected from the large multi-payer benchmark testing, 15 million members are randomly selected from the Medical Director reviews the results to verify that: 1. Prevalence rates for a condition are comparable to nationally published rates 2. Compliance rates for a condition are comparable to the rates reported in the published literature or by other national sources (e.g. HEDIS). If no comparable sources are available, the rates are judged based on what is clinically reasonable. In addition, all results are systematically reviewed for face validity by members of an external physician clinical consultant panel. 2f 2f.3 Provide Measure Scores from Testing or Current Use (description of scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance): 2g 2g. Comparability of Multiple Data Sources/Methods 2g 2g.1 Data/sample (description of data/sample and size): 2g 2g.3 Testing Results (e.g., correlation statistics, comparison of rankings): NA 2h. Disparities in Care 2h	data sample includes a geographically diverse 15 million member benchmark database. The database		
2f.3 Provide Measure Scores from Testing or Current Use (description of scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance): C P Summarized in 2b3 Q Comparability of Multiple Data Sources/Methods N 2g. Comparability of Multiple Data Sources/Methods 2g 2g 2g 2g.1 Data/sample (description of data/sample and size): 2g 2g 2g.2 Analytic Method (type of analysis & rationale): P M 2g.3 Testing Results (e.g., correlation statistics, comparison of rankings): N N 2h. Disparities in Care 2h C 2h	(type of analysis & rationale): During benchmark testing, 15 million members are randomly selected from the large multi-payer benchmark database and their claims data is processed through the software. The Medical Director reviews the results to verify that: 1. Prevalence rates for a condition are comparable to nationally published rates 2. Compliance rates for a measure are comparable to the rates reported in the published literature or by other national sources (e.g. HEDIS). If no comparable sources are available, the rates are judged based on what is clinically reasonable. In addition, all results are systematically reviewed for face validity by members of an external physician		
2g.1 Data/sample (description of data/sample and size): 2g 2g.2 Analytic Method (type of analysis & rationale): 2g 2g.3 Testing Results (e.g., correlation statistics, comparison of rankings): N	quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance):	C P M	
2g 2g 2g.2 Analytic Method (type of analysis & rationale): C P M 2g.3 Testing Results (e.g., correlation statistics, comparison of rankings): N NA NA 2h. Disparities in Care 2h	2g. Comparability of Multiple Data Sources/Methods		
2g.2 Analytic Method (type of analysis & rationale): C_ 2g.3 Testing Results (e.g., correlation statistics, comparison of rankings): N_ 2h. Disparities in Care 2h	2g.1 Data/sample (description of data/sample and size):		
2g.3 Testing Results (e.g., correlation statistics, comparison of rankings): N N N 2h. Disparities in Care 2h	2g.2 Analytic Method (type of analysis & rationale):	C P	ĺ
	2g.3 Testing Results (e.g., correlation statistics, comparison of rankings):	N	./
	2h. Disparities in Care		1
	2h.1 If measure is stratified, provide stratified results (scores by stratified categories/cohorts):		

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable

Comment [KP16]: 2e. For outcome measures and other measures (e.g., resource use) when indicated:

•an evidence-based risk-adjustment strategy (e.g., risk models, risk stratification) is specified and is based on patient clinical factors that influence the measured outcome (but not disparities in care) and are present at start of care, Error Bookmark not defined. OR rationale/data support no risk adjustment.

Comment [k17]: 13 Risk models should not obscure disparities in care for populations by including factors that are associated with differences/inequalities in care such as race, socioeconomic status, gender (e.g., poorer treatment outcomes of African American men with prostate cancer, inequalities in treatment for CVD risk factors between men and women). It is preferable to stratify measures by race and socioeconomic status rather than adjusting out differences.

Comment [KP18]: 2f. Data analysis demonstrates that methods for scoring and analysis of the specified measure allow for identification of statistically significant and practically/clinically meaningful differences in performance.

Comment [k19]: 14 With large enough sample sizes, small differences that are statistically significant may or may not be practically or clinically meaningful. The substantive question may be, for example, whether a statistically significant difference of one percentage point in the percentage of patients who received smoking cessation counseling (e.g., 74% v. 75%) is clinically meaningful; or whether a statistically significant difference of \$25 in cost for an episode of care (e.g., \$5,000 v. \$5,025) is practically meaningful. Measures with overall poor performance may not demonstrate much variability across providers.

Comment [KP20]: 2g. If multiple data sources/methods are allowed, there is demonstration they produce comparable results.

Comment [KP21]: 2h. If disparities in care have been identified, measure specifications, scoring, and analysis allow for identification of disparities through stratification of results (e.g., by race, ethnicity, socioeconomic status, gender):OR rationale/data justifies why stratification is not necessary or not feasible.

M

N

NA

2

сГ

2h.2 If disparities have been reported/identified, but measure is not specified to detect disparities, provide follow-up plans:

TAP/Workgroup: What are the strengths and weaknesses in relation to the sub-criteria for *Scientific Acceptability of Measure Properties?*

Steering Committee: Overall, to what extent was the criterion, *Scientific Acceptability of Measure Properties*, met?

Rationale:

3. USABILITY

Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making. (evaluation criteria)

3a. Meaningful, Understandable, and Useful Information

3a.1 Current Use: in use

3a.2 Use in a public reporting initiative (disclosure of performance results to the public at large) (*If* used in a public reporting initiative, provide name of initiative(s), locations, Web page URL(s). <u>If not</u> <u>publicly reported</u>, state the plans to achieve public reporting within 3 years):

Health plans, physicians (individuals and groups), care management, and other vendors/customers are using this measure on a national level. However, we do not know if this specific measure is being used as part of a public reporting initiative.

3a.3 If used in other programs/initiatives (*If used in quality improvement or other programs/initiatives, name of initiative(s), locations, Web page URL(s).* <u>*If not used for QI, state the plans to achieve use for QI within 3 years***):**</u>

Health plans, physicians (individuals and groups), care management, and other vendors/customers use many of our measures on a national level for quality improvement, disease management, and physician sharing programs. Customers are able to select their measures depending on their business needs. As such, we do not know which specific measures are used by our customers.

Testing of Interpretability (*Testing that demonstrates the results are understood by the potential users for public reporting and quality improvement*)

3a.4 Data/sample *(description of data/sample and size)*: Results are summarized and reported by users/customers depending on their business need - we do not have access to this information. Because of us my multiple users/customers, there is no single data sample, methodology, or public reporting format.

3a.5 Methods (e.g., focus group, survey, QI project):

3a.6 Results (qualitative and/or quantitative results and conclusions):

3b/3c. Relation to other NQF-endorsed measures

3b.1 NQF # and Title of similar or related measures: EC-093-08 Adult(s) with Frequent Use of Acute Medications that also Received Prophylactic Medications

(for NQF staff use) Notes on similar/related endorsed or submitted measures:

3b. Harmonization

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable



Comment [KP23]: 3b. The measure specifications are harmonized with other measures, and are applicable to multiple levels and settings.

Comment [KP22]: 3a. Demonstration that information produced by the measure is meaningful, understandable, and useful to the

intended audience(s) for <u>both</u> public reporting (e.g., focus group, cognitive testing) <u>and</u> informing quality improvement (e.g., quality

improvement initiatives). An important outcome that may not have an identified

to improvement.

improvement strategy still can be useful for

informing quality improvement by identifying

the need for and stimulating new approaches

Comment [k24]: 16 Measure harmonization refers to the standardization of specifications for similar measures on the same topic (e.g., *influenza immunization* of patients in hospitals or nursing homes), or related measures for the same target population (e.g., eye exam and HbAt for *patients with diabetes*), or definitions applicable to many measures (e.g., age designation for children) so that they are uniform or compatible, unless differences are dictated by the evidence. The dimensions of harmonization can include numerator, denominator, exclusions, and data source and collection instructions. The extent of harmonization depends on the relationship of the measures, the evidence for the specific measure focus, and differences in data sources.

45

3b

NQF #AC	P-042-10		
 3c. Distinctive or Additive Value 3c.1 Describe the distinctive, improved, or additive value this measure provides to existing NQF- endorsed measures: This measure addresses a different aspect of migraine care. Specifically, it identifies patients with poor migraine control who would benefit from a provider encounter to access the management plan. 5.1 Competing Measures If this measure is similar to measure(s) already endorsed by NQF (i.e., on the same topic and the same target population), describe why it is a more valid or efficient way to measure quality: see 3c.1 TAP/Workgroup: What are the strengths and weaknesses in relation to the sub-criteria for Usability? 	3c C P M N		Comment [KP25]: 3c. Review of existing endorsed measures and measure sets demonstrates that the measure provides a distinctive or additive value to existing NOF- endorsed measures (e.g., provides a more complete picture of quality for a particular condition or aspect of healthcare). Comment [k26]: 5. Demonstration that the measure is superior to competing measures - new submissions and/or endorsed measures (e.g., is a more valid or efficient way to measure).
Steering Committee: Overall, to what extent was the criterion, <i>Usability</i> , met? Rationale:	3 C P M N		
4. FEASIBILITY			
Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement. (evaluation criteria)	Eval Rating		
4a. Data Generated as a Byproduct of Care Processes	4a		Comment [KP27]: 4a. For clinical measures,
4a.1-2 How are the data elements that are needed to compute measure scores generated? coding/abstraction performed by someone other than person obtaining original information,	C P M N		required data elements are routinely generated concurrent with and as a byproduct of care processes during care delivery. (e.g., BP recorded in the electronic record, not abstracted from the record later by other personnel; patient self-assessment tools, e.g.,
4b. Electronic Sources			depression scale; lab values, meds, etc.)
 4b.1 Are all the data elements available electronically? (elements that are needed to compute measure scores are in defined, computer-readable fields, e.g., electronic health record, electronic claims) Yes 4b.2 If not, specify the near-term path to achieve electronic capture by most providers. 	4b C P M N		Comment [KP28]: 4b. The required data elements are available in electronic sources. If the required data are not in existing electronic sources, a credible, near-term path to electronic collection by most providers is specified and clinical data elements are specified for transition to the electronic health record.
4c. Exclusions			Comment [KP29]: 4c. Exclusions should not
4c.1 Do the specified exclusions require additional data sources beyond what is required for the numerator and denominator specifications? No	4c C P M N	_	require additional data sources beyond what is required for scoring the measure (e.g., numerator and denominator) unless justified as supporting measure validity.
4c.2 If yes, provide justification.			
4d. Susceptibility to Inaccuracies, Errors, or Unintended Consequences			Comment [KP30]: 4d. Susceptibility to
4d.1 Identify susceptibility to inaccuracies, errors, or unintended consequences of the measure and describe how these potential problems could be audited. If audited, provide results. Given the high threshold set in this measure to identify patients with poor migraine control, this measure will not identify all patients who would benefit from a provider encounter to review the migraine management plan. We are willing to accept this potential error rather than lowering the threshold and possibly identifying patients incorrectly as having poor control.	4d C P M N		inaccuracies, errors, or unintended consequences and the ability to audit the data items to detect such problems are identified.
4e. Data Collection Strategy/Implementation	4e	11	Comment [KP31]: 4e. Demonstration that the data collection strategy (e.g., source,
4e.1 Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data/missing data, timing/frequency of data	C P M		timing, frequency, sampling, patient confidentiality, etc.) can be implemented (e.g., already in operational use, or testing demonstrates that it is ready to put into operational use).
Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable	46		· · · ·

....

NQF #ACF	P-042-10
collection, patient confidentiality, time/cost of data collection, other feasibility/ implementation	N
issues: No modifications have been made based on testing or operational use of the measure.	
4e.2 Costs to implement the measure (costs of data collection, fees associated with proprietary	
measures): We do not have access to this information. This would vary based on the customer/vendor, patient	
population, and programs/interventions associated with measure use.	
4e.3 Evidence for costs:	
4e.4 Business case documentation:	
TAP/Workgroup: What are the strengths and weaknesses in relation to the sub-criteria for Feasibility?	4
Steering Committee: Overall, to what extent was the criterion, <i>Feasibility</i> , met? Rationale:	4 C□
RECOMMENDATION	N
(for NQF staff use) Check if measure is untested and only eligible for time-limited endorsement.	Time- limited
Steering Committee: Do you recommend for endorsement?	Y
Comments:	N A
CONTACT INFORMATION	
Co.1 Measure Steward (Intellectual Property Owner)	
Co.1 Organization Ingenix 12125 Technology Drive Eden Prairie Minnesota 55344	
Co.2 Point of Contact Kay Schwebke, Medical Director kay.schwebke@ingenix.com 952-833-7154	
Measure Developer If different from Measure Steward	
Co.3 <u>Organization</u> Ingenix 12125 Technology Drive Eden Prairie Minnesota 55344	
Co.4 Point of Contact	
Kay Schwebke, Medical Director kay.schwebke@ingenix.com 952-833-7154	
Co.5 Submitter If different from Measure Steward POC Kay Schwebke, Medical Director kay.schwebke@ingenix.com 952-833-7154- Ingenix	
Co.6 Additional organizations that sponsored/participated in measure development This measure has been reviewed and supported by the American Academy of Family Physicians.	
ADDITIONAL INFORMATION	
Workgroup/Expert Panel involved in measure development Ad.1 Provide a list of sponsoring organizations and workgroup/panel members' names and organizations Describe the members' role in measure development. We have an external consultant panel that participates in the original literature search process, measure development, code set review, testing review, and maintenance processes. Panel members include the follo	
· · · · · · · · · · · · · · · · · · ·	9

	NQF #ACP-042-10
Alexander, Beth Pharm D, BCPS Assistant Professor, Augsburg College Ayenew, Woubeshet, MD Hennepin Faculty Associates; Hennepin County Medical Center	
Becker, Keith, MD Fairview Medical Center Betcher, Susan, MD Allina Medical Clinic	
Bruer, Paul, MD Comprehensive Ophthamology, LLC	
Capecchi, Joseph, MD Allina Medical Clinic Giesler, Janell, MD Allina Medical Clinic	
Grabowski, Carol, MD Allina Medical Clinic	
Hansen, Calvin, MD Iowa Health Physicians Hargrove, Jody, MD Arthritis and Rheumatology Consultants	
Hermann, Richard, MD Tufts - New England Medical Center	
Jemming, Brian, Pharm D CentraCare Health System	
Kohen, Jeffrey, MD Veterans Affairs Medical Center McCarthy, Teresa, MD University of Minnesota, Department of Family	
Medicine & Community Health	
McEvoy, Charlene, MD, MPH HealthPartners & HealthPartners Research Foundation; Assistant Professor of Medicine,	
University of Minnesota	
McGee, Deanna, Pharm D, BCPS Retail Pharmacy	
Ogle, Kathleen, MD Hennepin Faculty Associates; Hennepin County Medical Center: Assistant Professor of	
Medicine, University of Minnesota Medical School	
Peter, Kathleen, MD Park Nicollet Medical Center	
Pieper-Bigelow, Christina, MD Allina Medical Clinic Redmon, Bruce, MD University of Minnesota Physicians	
Scharpf, Steven, MD Mountain Valleys Health Centers	
Weitz, Carol, MD Independent	
Ad.2 If adapted, provide name of original measure: Ad.3-5 If adapted, provide original specifications URL or attachment	
Measure Developer/Steward Updates and Ongoing Maintenance Ad.6 Year the measure was first released: 2006	
Ad.7 Month and Year of most recent revision: 2007-08	
Ad.8 What is your frequency for review/update of this measure? every three years at minimum Ad.9 When is the next scheduled review/update for this measure? 2010-02	m
Ad.10 Copyright statement/disclaimers: The information in this document is subject to change	without notice
This documentation contains proprietary information in this document is subject to change rights reserved. No part of this documentation may be reproduced or transmitted in any form or electronic or mechanical, including photocopying, modifying, or recording, without the prior wri- Ingenix, Inc. No part of this documentation may be translated to another program language with written consent of Ingenix, Inc.	copyright. All by any means, tten permission of
© 2009 Ingenix, Inc.	
HEDIS is a registered trademark of the National Committee for Quality Assurance (NCQA).	
National Committee for Quality Assurance (NCQA) Notice:	
HEDIS® 2009 Measure Specification: The HEDIS® measures and specifications were developed by the National Committee for Quality Assurance ("NCQA"). The HEDIS measures and specifications guidelines and do not establish standards of medical care. NCQA makes no representations, warr endorsement about the quality of any organization or physician that uses or reports performance data or rates calculated using the HEDIS measures and specifications and NCQA has no liability to on such measures or specifications. © 2008 National Committee for Quality Assurance, all rights	are not clinical anties, or e measures or any o anyone who relies
The following rule types indicate NCQA HEDIS rules: NS-H and NSHA. American Medical Association Notice:	

CPT only © 2008 American Medical Association. All rights reserved.
Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA,
are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice
medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
CPT is a registered trademark of the American Medical Association.
The following rule type indicates AMA rules: NS-A.
U.S. Government Rights:
This product includes CPT® and/or CPT® Assistant and/or CPT® Changes which is commercial technical data
and/or computer data bases and/or commercial computer software and/or commercial computer software
documentation, as applicable which were developed exclusively at private expense by the American Medical
Association, 515 North State Street, Chicago, Illinois, 60610. U.S. Government rights to use, modify, reproduce,
release, perform, display, or disclose these technical data and/or computer data bases and/or computer software
and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-
7015(b)(2) (November 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS
227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights
restrictions of FAR 52.227-14 (June 1987) and/or subject to the restricted rights provisions of FAR 52.227-14 (June
1987) and FAR 52.227-19 (June 1987), as applicable, and any applicable agency FAR Supplements, for non-
Department of Defense Federal procurements.
Applicable FARS/DFARS Restrictions Apply to Government Use
CDT-4 codes and descriptions are © copyright 2008 American Dental Association. All rights reserved. Reproduction
in any media of all or any portion of this work is strictly prohibited without the prior written consent of American
Dental Association.

Ad.11 -13 Additional Information web page URL or attachment: Attachment Migraine appendix.doc Date of Submission (*MM/DD/YY*): 02/05/2010

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable

1c. The measure focus is:
 an outcome (e.g., morbidity, mortality, function, health-related quality of life) that is relevant to, or associated with, a national health goal/priority, the condition, population, and/or care being addressed;
OR
• if an intermediate outcome, process, structure, etc., there is evidence that supports the specific measure focus
as follows:
o Intermediate outcome - evidence that the measured intermediate outcome (e.g., blood pressure, Hba1c)
leads to improved health/avoidance of harm or cost/benefit.
o Process - evidence that the measured clinical or administrative process leads to improved health/avoidance
of harm and
if the measure focus is on one step in a multi-step care process, it measures the step that has the greatest

Karen Pace

10/5/2009 8:59:00 AM

Page 3: [1] Comment [k4]

if the measure focus is on one step in a multi-step care process, it measures the step that has the greatest effect on improving the specified desired outcome(s).

- o <u>Structure</u> evidence that the measured structure supports the consistent delivery of effective processes or access that lead to improved health/avoidance of harm or cost/benefit.
- o <u>Patient experience</u> evidence that an association exists between the measure of patient experience of health care and the outcomes, values and preferences of individuals/ the public.
- o <u>Access</u> evidence that an association exists between access to a health service and the outcomes of, or experience with, care.
- o <u>Efficiency</u> demonstration of an association between the measured resource use and level of performance with respect to one or more of the other five IOM aims of quality.

Page 3: [2] Comment [k5] Karen Pace	10/5/2009 8:59:00 AM
-------------------------------------	----------------------

4 Clinical care processes typically include multiple steps: assess \rightarrow identify problem/potential problem \rightarrow choose/plan intervention (with patient input) \rightarrow provide intervention \rightarrow evaluate impact on health status. If the measure focus is one step in such a multi-step process, the step with the greatest effect on the desired outcome should be selected as the focus of measurement. For example, although assessment of immunization status and recommending immunization are necessary steps, they are not sufficient to achieve the desired impact on health status - patients must be vaccinated to achieve immunity. This does not preclude consideration of measures of preventive screening interventions where there is a strong link with desired outcomes (e.g., mammography) or measures for multiple care processes that affect a single outcome.



The information in this document is subject to change without notice. This documentation contains proprietary information, and is protected by U.S. and international copyright. All rights reserved. No part of this documentation may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, modifying, or recording, without the prior written permission of Ingenix, Inc. No part of this documentation may be translated to another program language without the prior written consent of Ingenix, Inc.

© 2008 Ingenix, Inc.

Release 7.0, Technical Guide for Windows, February 2008

National Committee for Quality Assurance (NCQA) Notice:

HEDIS 2007 Measure Specification

The HEDIS[®] measures and specifications were developed by and are owned by the National Committee for Quality Assurance ("NCQA"). The HEDIS measures and specifications are not clinical guidelines and do not establish standards of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures or any data or rates calculated using the HEDIS measures and specifications and NCQA has no liability to anyone who relies on such measures or specifications. ©2006 National Committee for Quality Assurance, all rights reserved.

'NS-H' and 'NSHA' indicate NCQA HEDIS rules.

HEDIS is a registered trademark of the National Committee for Quality Assurance (NCQA).

American Medical Association Notice:

CPT only © 2007 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association

'NS-A' indicates AMA rules.

U.S. Government Rights:

This product includes CPT[®] and/or CPT[®] Assistant and/or CPT[®] Changes which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, 515 North State Street, Chicago, Illinois, 60610. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (November 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (June 1987) and/or subject to the restricted rights provisions of FAR 52.227-14 (June 1987) and FAR 52.227-19 (June 1987), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.

Applicable FARS/DFARS Restrictions Apply to Government Use.

CDT-4 codes and descriptions are © copyright 2007 American Dental Association. All rights reserved. Reproduction in any media of all or any portion of this work is strictly prohibited without the prior written consent of American Dental Association.

Ingenix 950 Winter Street, Suite 3800 Waltham, MA 02451 Customer Support: Tel: 866.818.7424 Fax: 781.895.9951 SymmetrySuite.Support@ingenix.com



What Input Files to Prepare

The following list specifies what input files you prepare for processing:

- · The claims data file (required)
- The member data file (required) ٠
- The member term data file (required) ٠



Field Type Definitions and Input File Requirements

This chapter lists the field requirements for your input files. One of the attributes listed among the requirements is defined as "Type". There are four field types used to describe a field's value, and they are defined below.

Field Type	Definition
AlphaNum	A value made of letters and/or numbers. If a value of this type is made of numbers only, it will not be a value that can be operated on mathematically. For example, it would be inappropriate to subtract one procedure code from another procedure code even though both values may contain only numbers.
Num	A value made of numbers only, and which can logically be operated on mathematically. Age is an example of this type.
	One particular field, while not used in mathematical calculations, is defined in the EBM Connect software as such that it accepts only numeric values. (To enter a non-numeric value would cause EBM Connect processing to stop.) Therefore, this field is defined as Num. It is the Case ID field in the optional disease registry input file.
Date	A value which can be interpreted as a date value. Values should always use four-digit years but the format may vary otherwise.
DecNum	A value made of numbers and a decimal point. These values can also logically be operated on mathematically.

Claims Input File

The claims file contains detailed information on services that were billed or performed or otherwise rendered. The claims file includes:

- · Medical claims, including medical services, facility services and clinic services
- Pharmacy claims, including billed prescriptions and drugs
- · Lab claims, including lab test and results information

Field Name	Туре	Length	Required or Optional
Family ID	AlphaNum	1-30	Always required for all claims
Patient ID	AlphaNum	0-2	Optional
Amount Paid	DecNum	1-11	Required for all claims
Amount Allowed	DecNum	0-11	Required for all claims
Procedure Code	AlphaNum	5	Required if there is no revenue code, NDC, or LOINC® code
Procedure Code Modifier	AlphaNum	2	Required for medical claims
Revenue Code	AlphaNum	0 or 4	Optional (applies to medical claims when used)
First Diagnosis Code	AlphaNum	5 or 6	Required for medical claims
Second Diagnosis Code	AlphaNum	0, 5 or 6	Optional (applies to medical claims when used)
Third Diagnosis Code	AlphaNum	0, 5 or 6	Optional (applies to medical claims when used)
Fourth Diagnosis Code	AlphaNum	0, 5 or 6	Optional (applies to medical claims when used)
First Date of Service	Date	8 or 10	Always required for all claims
Last Date of Service	Date	8 or 10	Required for all claims

INGENIX.

Input Guide

Paid Date	Date	0, 8 or 10	Optional
Type of Service	AlphaNum	0-10	Optional
Provider ID	AlphaNum	1-20	Required for medical claims
Ordering Provider ID	AlphaNum	0-20	Optional
Provider Type	AlphaNum	1-10	Required for medical claims
Provider Specialty Type	AlphaNum	1-10	Required for medical claims
Provider Key	AlphaNum	1-20	Required for medical claims
NDC	AlphaNum	0 or 11	Required for Rx claims
Day Supply	Num	0-4	Required for Rx claims
Quantity Count	DecNum	0-10	Required for Rx claims
LOINC®	AlphaNum	0 or 7	Required for lab claims
Lab Test Result	AlphaNum	0-18	Required for lab claims
Place of Service	AlphaNum	1-10	Required for medical claims
Unique Record ID	AlphaNum	1-28	Required for all claims
Claim Number	AlphaNum	1-28	Required for all claims
Bill Type Frequency Indicator	Num	0 or 1	Optional
Patient Status	AlphaNum	1-2	Required for facility claims (involving admission or confinement).
Facility Type	AlphaNum	0-2	Optional
Bed Type	AlphaNum	0-1	Optional
First ICD-9 Procedure Code	AlphaNum	0, 4 or 5	Optional, but will impact results (applies to medical claims when used)
Second ICD-9 Procedure Code	AlphaNum	0, 4 or 5	Optional (see above)
Third ICD-9 Procedure Code	AlphaNum	0, 4 or 5	Optional (see above)
Fourth ICD-9 Procedure Code	AlphaNum	0, 4 or 5	Optional (see above)

Field Descriptions

Instructions for each input field are as follows:

Family ID

This field identifies all members of a family and can be any alphanumeric string.

Note: Remember that each Family ID (and Patient ID) listed in your claims input file must have a corresponding record in your member input data file and your member term data file.



Patient ID

This field identifies individual members within a family. If present, this field must be sorted within Family ID, so that all records for an individual are contiguous. If the Family ID uniquely identifies an individual, this field need not be specified (that is, its length in the dictionary will be zero).

Amount Paid

The amount paid for this claim line.

Amount Allowed

The allowed amount for this claim line. This amount typically represents the total amount reimbursed including deductibles, copays, coinsurance, insurer paid, etc.

Procedure Code

The procedure code must be one of:

- A procedure code specified in the Physician's Current Procedure Terminology, 4th Edition (CPT[®]-4 codes) defined by the American Medical Association, for the years 1997 and later.
- A procedure code specified by the HCFA Common Procedure Coding System, Level II code (HCPCS) defined by the Centers for Medicare and Medicaid Services (CMS) for the years 1999 and later.
- A National Uniform Billing Committee (NUBC) revenue code.

Note: When the NUBC code is entered in the Procedure Code field, it should be padded to the right with blanks because the Procedure Code field always occupies five characters.

If your organization defines its own procedure codes and/or revenue codes, they must be mapped to standard procedure and revenue codes.

Procedure Code Modifier

Use this field to specify any procedure code modifier that accompanies the procedure code.

Revenue Code

The revenue code, if one was entered for the claim. Supported values in this field are NUBC revenue codes. If your organization defines its own revenue codes, they must be mapped to standard revenue codes.

The revenue code is an optional field, allowing you to define your input records so that you can place an NUBC revenue code and a CPT/HCPCS procedure code on a single record line.

For claim records that do not have a revenue code, leave the revenue code field blank.

INGENIX. Input Guide

First Diagnosis Code Through Fourth Diagnosis Code

Up to four diagnoses may be entered for each claim, but only the first is required.

If your organization defines its own diagnosis codes, they must be mapped to standard ICD-9 diagnosis codes.

First Date of Service and Last Date of Service

The first date and last date represented by the claim line. If you choose to use a date format with separators (such as YYYY/MM/DD or YYYY-MM-DD), the separators are ignored on input, so you can use any character as a separator. Valid formats include: YYYYMMDD, MMDDYYYY, DDMMYYYY, YYYY/MM/DD, MM/DD/ YYYY, and DD/MM/YYYY, where the separator can be any character.

Paid Date

This field is optional. This is the date the claim was paid. The format of the paid date must be the same as that used in the First and Last Date of Service.

Type of Service

This is an optional code which represents the type of service (TOS) performed for this claim. If no specific value is available for this field, it should be filled with blanks. If this field is not used (i.e., its length is set to zero in the configuration), non-pharmaceutical claims with no procedure code will be treated as ancillary records.

Provider ID

Provider identification number from the claim. Used to identify who performed the service.

Ordering Provider ID

This is an optional field. This is the identification number of the provider who ordered the service.

Provider Type

This code represents the type of provider who performed the service. Examples of provider types would be chiropractor, nurse practitioner, medical doctor, counselor, pharmacy, hospital or treatment facility.

Provider Specialty Type

This code represents the specialty of the provider who performed the service.

Provider Key

Unique number or code for a physician who has multiple provider IDs or specialties. A single health care provider may have multiple provider IDs in your input claims data, but this person or entity should have only one provider key.

INGENIX.

Input Guide

NDC

If this is a pharmaceutical claim, this field should contain the drug's NDC code. For nonpharmaceutical claim records, the NDC field should be filled with blanks.

Day Supply

For pharmacy records, the number of days a filled prescription is expected to last. If you have no pharmacy records, the Days Supply is an optional field.

Quantity Count

Quantity of drug dispensed in metric units:

Each - solid oral dosage forms (tablet, capsule), powder filled (dry) vials, packets, patches, units of use packages, suppositories, bars.

Milliliter - (cc) liquid oral dosage forms, liquid filled vials, ampules, reconstituted oral products.

Grams - ointments, bulk powders (not IV). If you have no pharmacy records, the Quantity Count is an optional field.

LOINC®

Logical Observation Identifiers Names and Codes (LOINC[®]). The LOINC Code is a universal identifier for a lab test for a particular analyte. The LOINC User's Guide and database can be found at www.regenstrief.org.

Enter a LOINC code if the record is a lab record. For non-lab records, leave the LOINC field blank.

If you have no lab records in your claims input, the LOINC code is optional.

Notes:

- (1) When using lab results data that has not been mapped to a LOINC code, map the comparable vendor-specific test number provided by the laboratory vendor(s) to one of these default codes.
- (2) This is a retired code which may be present on historical data, or which some laboratories may be continuing to use. Input record data with this code is included in the definition of this test.

Lab Test Result

If the record is a lab record, use this field to enter the result value of lab test. For nonlab records, this field should be blank.

If you have no lab records in your claims input, the Lab Test Result is optional.

Place of Service

Place of service (POS). You must map your internal POS codes to Centers for Medicare and Medicaid Services (CMS) standard POS codes.

Page 8 of 12

Confidential and Proprietary. Recipient of this information may not disclose, permit to be disclosed, or otherwise resell or transfer all or any portion of this information to any third party. Input Guide_NQF-634007901545951692.doc



Input Guide

Unique Record ID

This required field contains a unique identifier representing the service line from the claim. For medical services, this ID typically represents the service row from the CMS 1500 or CMS 1450/UB92 claim form.

Claim Number

A unique identifier used to link service lines for a specific claim submitted for a member. If a claim has multiple service lines, each service will have a unique record ID and the same claim number to represent the claim.

Bill Type Frequency Indicator

This optional field is used to indicate the disposition of confinements.

Patient Status

This field is required for facility claims. The contents will be the patient status indicator field from the NUBC UB-92 form. This field can denote whether the member died during a confinement.

Facility Type

This field is optional. Space for it is provided to allow for additional post grouping analysis. The contents will typically be the UB-92 facility type data value. This would allow records to be easily selected for diagnosis related grouping (DRG) based on the facility type.

Bed Type

If a value is present, this field acts as an additional discriminator in determining whether a Facility record extends an existing confinement or starts a new confinement.

First ICD-9 Procedure Code Through Fourth ICD-9 Procedure Code

If your claims have ICD-9 procedure codes, include them in your claims input file.

If a decimal point will appear in this field in your claim records, the length should be given as 5. If the decimal separator is not used, the length is 4. If these fields are unused, the length is zero.

INGENIX. Input Guide

Member Input File

The member data file contains the most current information about the member.

Field Descriptions

Field	Туре	Length	Required or Optional
Family ID	AlphaNum	1-30	Required
Patient ID	AlphaNum	0-2	Optional
Patient Gender	AlphaNum	1	Required
Date of Birth	Date	8 or 10	Required
Member Beginning Eligibility Date	Date	0, 8 or 10	Optional
Member Ending Eligibility Date	Date	0, 8 or 10	Optional

Instructions for each input field are as follows:

Family ID

This field identifies all members of a family and can be any alphanumeric string. The records in the member file must be sorted first on the Family ID (together with Patient ID, if available) so that all records for an individual are contiguous.

Patient ID

This field identifies individual members within a family. If present, this field must be sorted within Family ID, so that all records for an individual are contiguous. If the Family ID uniquely identifies an individual, this field need not be specified (that is, its length in the dictionary will be zero).

Patient Gender and Date of Birth

The member's gender (F or M) and date of birth. If you choose to use a date format with separators (such as YYYY/MM/DD or YYYY-MM-DD), the separators are ignored on input, so you can use any character as a separator. Valid date formats include: YYYYMMDD, MMDDYYYY, DDMMYYYY, YYYY/MM/DD, MM/DD/YYYY, and DD/MM/YYYY, where the separator can be any character.

Member Beginning Eligibility Date and Ending Eligibility Date

The first date on which the member became covered under the plan and the last date of the member's coverage. If you choose to use a date format with separators (such as YYYY/MM/DD or YYYY-MM-DD), the separators are ignored on input, so you can use any character as a separator. Valid formats include: YYYYMMDD, MMDDYYYY, DDMMYYYY, YYYY/MM/DD, MM/DD/YYYY, and DD/MM/YYYY, where the separator can be any character.

INGENIX. Input Guide

Member Term Input File

The member term data file contains member coverage and term activity information. Plan coverage begin and end dates are required in order to correctly calculate the other fields in the member term file. There may be more than one record per individual member.

Field Descriptions

Field	Туре	Length	Required or Optional
Family ID	AlphaNum	1-30	Required
Patient ID	AlphaNum	0-2	Optional
Member Beginning Eligibility Date	Date	8 or 10	Required
Member Ending Eligibility Date	Date	8 or 10	Required
Primary Care Provider	AlphaNum	20	Required
Provider Specialty Type	AlphaNum	1-10	Required
Medical Flag	AlphaNum	1	Required
Pharmacy Flag	AlphaNum	1	Required

Instructions for each input field are as follows:

Family ID

This field identifies all members of a family and can be any alphanumeric string. The records in the member term file must be sorted first on the Family ID (together with Patient ID, if available) so that all records for an individual are contiguous.

Patient ID

This field identifies individual members within a family.

Member Beginning Eligibility Date and Member Ending Eligibility Date

The first date on which the member became covered under the plan and the last date of the member's coverage. If you choose to use a date format with separators (such as YYYY/MM/DD or YYYY-MM-DD), the separators are ignored on input, so you can use any character as a separator. Valid formats include: YYYYMMDD, MMDDYYYY, DDMMYYYY, YYYY/MM/DD, MM/DD/YYYY, and DD/MM/YYYY, where the separator can be any character.

Primary Care Provider

The provider key for the member's primary care physician. A single health care physician may have multiple provider IDs in your input claims data, but this person should have only one provider key.

INGENIX.

Input Guide

Provider Specialty Type

This code represents the specialty of the primary care physician.

Medical Flag

Identifies whether the member has medical coverage (Y or N).

Pharmacy Flag

Identifies whether the member has pharmacy coverage (Y or N).

Appendix

The purpose of the following methodology is to identify patients that have frequent migraine headaches. It is not possible to directly identify headaches; therefore, quantification of acute migraine medications against a threshold is used as a proxy for frequent headaches. Frequent migraine headaches are defined as 4 per month. Five types of migraine headache medications will be analyzed separately to determine whether or not a patient has frequent migraine headaches.

Thresholds were defined based on 12 headaches during a 90-day period

- 1. Triptan contain medications
 - Oral 36 tablets within 90 days
 - Subcutaneous 24 dose equivalents within 90 days
 - Nasal spray 24 spray bottles within 90 days
- 2. Butorphanol Tartrate (e.g., Stadol NS)
 - Nasal Squeeze Bottle 12.5 mL within 90 days
- 3. Dihydroergotamine Mesylate
 - Ampule 12 mL within 90 days
- 4. Butalbital (e.g., Fioricet and Fiorinal)
 - Oral 100 tablets or capsules within 90 days
- 5. Midrin type medication
 - Oral 150 capsules within 90 days

1. ORAL TRIPTAN

- a. Quantity count for this drug is in tablets
- b. Two-three tablets treat one headache. For the purpose of calculation, assume three tablets per headache.

c. Threshold: 36 tablets Oral Triptan

- d. Methodology:
 - i. Sum Quantity Count where Drug Concept ID = 122
 - ii. Compare the result from i to threshold of 36 tablets

2. SUBCUTANEOUS TRIPTAN

i. Create a SUMATRIPTAN SUCCINATE dose equivalent

A. SUMATRIPTAN SUCCINATE KIT PACKAGES

- a. Quantity count for this drug is in kits
- b. One kit contains two single dose syringe cartridges
- c. Two single dose syringes are used to treat one headache
- d. One kit SUMATRIPTAN SUCCINATE = 2 SUMATRIPTAN SUCCINATE dose equivalent

B. SUMATRIPTAN SUCCINATE VIAL PACKAGES

- a. Quantity count for this drug is in mLs
- b. Packed in 0.5 mL single dose vials in cartons of 5 vials. Each vial contains 6 mg of active ingredient.
- c. One two 0.5 mL vials are used to treat one headache.
- d. <u>1 mL SUMATRIPTAN SUCCINATE = 2 SUMATRIPTAN SUCCINATE dose equivalent</u>

ii. Threshold: 24 dose equivalents SUMATRIPTAN SUCCINATE

- iii. Methodology:
 - a. Sum Quantity Count where Drug Concept ID = 123
 - b. Multiply Sum of Quantity Count by 2
 - c. Compare to threshold of 24 dose equivalents

3. NASAL TRIPTAN (SUMATRIPTAN Nasal Spray)

- a. Quantity count for this drug is in bottles
- b. Packed in six single use spray bottles
- c. Two spray bottles are used to treat one headache
- d. Threshold: 24 spray bottles SUMATRIPTAN
- e. Methodology:
 - i. Sum Quantity Count where Drug Concept ID = 121
 - ii. Compare the result from i to threshold of 24 spray bottles

4. BUTORPHANOL TARTRATE (e.g., Stadol NS)

- a. Quantity count for this drug is in mLs
- b. Packed in 2.5 ml squeeze bottles
- c. One 2.5 mL squeeze bottle is used to treat 2 to 3 headaches.

d. Threshold: 12.5 mL BUTORPHANOL TARTRATE

- e. Methodology:
 - i. Sum Quantity Count where Drug Concept ID = 29
 - ii. Compare the result from i to threshold of 12.5 mL

5. DIHYDROERGOTAMINE MESYLATE NASAL SPRAY (e.g., Migranal)

- a. Quantity count for this drug is in mLs
- b. Packed in 4 mL kits
- c. One 4 mL kit is used to treat 4 headaches.
- d. Threshold: 12 mL DIHYDROERGOTAMINE MESYLATE NASAL SPRAY
- e. Methodology:
 - i. Sum Quantity Count where Drug Concept ID = 42
 - ii. Compare the result from i to threshold of 12 mL

6. DIHYDROERGOTAMINE MESYLATE INJECTION (e.g., D.H.E.45)

- a. Quantity count for this drug is in mLs
- b. Packed in 1 mL ampules
- c. One 1 ml ampule is used to treat 1 headache.
- d. Threshold: 12 mL DIHYDROERGOTAMINE MESYLATE INJECTION
- e. Methodology:
 - i. Sum Quantity Count where Drug Concept ID = 174
 - ii. Compare the result from i to threshold of 12 mL

7. BUTALBITAL containing Medication (e.g., Fioricet and Fiorinal)

- a. Quantity count for this drug is in tablets/capsules
- b. 8 tablets/capsules are used to treat one headache
- c. Threshold: 100 tablets/capsules BUTALBITAL
- d. Methodology:
 - i. Sum Quantity Count where Drug Concept ID = 28
 - ii. Compare the result from i to threshold of 100 tablets/capsules

8. Midrin-type Medication

- a. Quantity count for this drug is in capsules
- b. 12 capsules are used to treat one headache
- c. Threshold: 150 capsules Midrin-type Medication
- d. Methodology:

- i. Sum Quantity Count where Drug Concept ID = 76
- ii. Compare the result from i to threshold of 150 capsules

Acute Migraine Medications

No.	Code Set Name	Drug Concept ID	Conversion Factor (ConFactor)	Conversion Formula (1, 2, 3)	Threshold
1.	Oral Triptan	122	1.0	Qty Ct * ConFactor = Eq Dose	36
2.	Subcutaneous Triptan	123	2.0	Qty Ct * ConFactor = Eq Dose	24
3.	Nasal Triptan	121	1.0	Qty Ct * ConFactor = Eq Dose	24
4.	BUTORPHANOL TARTRATE	29	1.0	Qty Ct * ConFactor = Eq Dose	12.5
5.	DIHYDROERGOTAMINE MESYLATE NASAL SPRAY	42	1.0	Qty Ct * ConFactor = Eq Dose	12
6.	DIHYDROERGOTAMINE MESYLATE INJECTION	174	1.0	Qty Ct * ConFactor = Eq Dose	12
7.	BUTALBITAL containing Medication	28	1.0	Qty Ct * ConFactor = Eq Dose	100
8.	Midrin-type Medication	76	1.0	Qty Ct * ConFactor = Eq Dose	150

1. Qty Ct - Quantity Count, a field on the pharmacy claim record

2. ConFactor - Conversion Factor, a value defined in the Clinical Definition Library (CDL)

3. Eq Dose - Equivalent Dose, a computed value

- i. Include pharmacy claims, as defined by the above code set(s), with a fill date during the last 120 days of the report period. (Note: Use 120 days rather than 90 days, because the last script is excluded.)
- ii. Within each code set, exclude the last (most current) script (Rationale: Each subsequent script indicates the patient has used the medication from the previous script. This methodology strengthens the likelihood that patients identified are frequent users.) Note: If there is only one eligible script within a code set, that drug will be excluded.
- iii. Within each code set, compute TOTAL Equivalent Dose by summing the Equivalent Dose across all eligible claims within that code set. Compare TOTAL Equivalent Dose for this code set to the corresponding Threshold.

iv. Repeat for each code set.